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I.  
 
INTRODUCTION 
MDS and MDR-AML  
Myelodysplastic syndrome (MDS), also known as preleukemia, refers to a group of 
clonal disorders of unknown cause in which the bone marrow functions abnormally and fails 
to produce mature blood cells in adequate numbers.  MDS affects the production of red 
blood cells, platelets, and neutrophils (Bennett, Catovsky et al. 1982; Bernell, Jacobsson et al. 
1996).  MDS progresses to acute myeloid leukemia (AML) in about 30 percent of patients 
and is directly fatal in most of the rest.  Although MDS is most common in adults over the 
age of 50 (median age estimated at 65-70 years old), it also occurs in children and younger 
adults.  There are four main types of MDS: refractory anemia, refractory anemia with ring 
sideroblasts, refractory cytopenia with multilineage dysplasia., and refractory anemia with 
excess blasts (Nosslinger, Reisner et al. 2001).  Distinction between the subtypes of MDS is 
largely based on the proportion of blasts in the peripheral blood (PB) and bone marrow 
(BM), the degree of dysplasia in hematopoietic precursors, and the presence of clonal 
cytogenetic abnormalities.  The BM blast count has a major influence on prognosis in MDS 
(Greenberg, Cox et al. 1997).  There are no highly specific and sensitive diagnostic markers 
available for MDS.  Allogeneic bone marrow transplantation (transfusion using marrow from 
a compatible donor) is currently the most effective form of treatment for most types of 
MDS.  However, most patients have high risk for this procedure due to their advanced age; 
and even with this procedure, up to 30-40% of patients relapse (Bennett, Catovsky et al. 
1982).   
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Approximately 50% of AML cases follow or are biologically related to MDS.  The 
pathogenesis of MDS and subsequent MDS related AML (MDR-AML) is unknown, and it is 
not possible to consistently separate these AML cases from the remainder of cases, true de 
novo AML (TDN-AML).  Accurate distinction between these disease sets would likely 
improve patient outcomes, since treatment differs substantially for MDR- versus TDN- 
AML (Head 1996).  The cytogenetic differences and differing response to therapy of these 
two groups of AML appear to reflect the underlying biologic differences of the two diseases.  
TDN-AML is a chemotherapy-sensitive disease characterized by specific recurring 
translocations, whereas MDS and MDR-AML are characterized by numerous chromosomal 
abnormalities and are typically resistant to chemotherapy or other current treatment except 
for stem cell transplantation (SCT).  Because of its age distribution (occurring in elderly 
people), most patients are ineligible for SCT (Head 2002).   
The pathogenesis of MDS and MDR-AML is unknown, but some data suggest a 
relationship to interstrand cross-link (ICL) DNA damage (Dronkert and Kanaar 2001). One 
example is seen in therapy-related MDR-AML.  Some cancer patients develop MDR-AML 
after they undergo chemotherapy treatment with DNA cross-linking agents (Anderson, 
Kopecky et al. 2002).  Another example is found in MDS and MDR-AML that develop in 
patients with Fanconi Anemia, an inherited deficiency in repair of cross-link DNA damage.  
Thus, ICL DNA damage is implicated in the pathogenesis of at least some cases of MDS 
and MDR-AML (Auerbach 1992; Head 1996; Lensch, Tischkowitz et al. 2003).  However, 
the repair system for correcting such damage is largely unknown (Islas, Vos et al. 1991; Vos 
and Wauthier 1991; Larminat, Zhen et al. 1993; Wiencke and Wiemels 1995; Lawley and 
Phillips 1996; Buchwald and Moustacchi 1998; Dronkert and Kanaar 2001).  
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Fanconi Anemia, DNA Cross-Linking Agents And MDS And MDR –AML 
Fanconi anemia (FA) is an autosomal recessive disease, and affected patients present 
with a diverse assortment of congenital malformations, the most common being limb 
malformations and abnormal skin pigmentation (Auerbach 1992; Buchwald and Moustacchi 
1998; Clarke, Marsh et al. 1998). Progressive bone marrow (BM) failure and its 
complications are the major causes of death of FA, and bone marrow transplant is currently 
the only curative treatment available.  FA patients are also predisposed to developing cancer, 
particularly MDS and MDR-AML (Auerbach 1992; Buchwald and Moustacchi 1998).  
Cells cultured from FA patients display an increased level of spontaneous 
chromosomal abnormalities when compared to normal cells, and this effect is amplified 
when the cells are exposed to DNA cross-linking agents such as mitomycin C (MMC).  For 
this reason, FA has been classified as a chromosomal instability disorder.  Cellular sensitivity 
to DNA cross-linking agents is currently used as a diagnostic test for FA (Pritsos and 
Sartorelli 1986; Tomasz 1995). 
DNA Cross-Linking Agents 
DNA cross-linking agents cause cross-links both inside each DNA strand (DNA 
intrastrand cross-links) and between two complementary strands (DNA interstrand cross-
links).  ICLs are among the most toxic of insults to DNA.  A single ICL can kill repair-
deficient bacteria and yeast, and about 40 ICLs can kill repair-deficient mammalian cells 
(Lawley and Phillips 1996).  Moreover, ICLs can induce mutations and rearrangements of 
DNA by incorporation of DNA damage into the genome.  Such mutation may result in 
some instances in acquisition of uncontrolled cell growth and tumor formation, as in MDS 
and MDR-AML.  Many different agents are capable of inducing ICLs in the genome.  A 
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well-known class of ICL-inducers is chemotherapeutic agents like MMC, cisplatin, nitrogen 
mustard, nitrosourea, and their derivatives.   
Organisms have developed strategies to deal with DNA damage in order to survive.  
A number of specialized repair pathways have evolved, each of which processes specific 
kinds of DNA damage.  An intriguing aspect of ICL repair is that several of these pathways 
apparently have to work together in order to remove or bypass an ICL (Larminat, Zhen et al. 
1993; Chu 1994; Dronkert and Kanaar 2001).  While the major ICL repair pathway in 
bacteria is well-characterized, both genetically and biochemically, ICL repair in eukaryotes is 
less well understood (Dronkert and Kanaar 2001).  
ICL agents have different toxicities depending on a number of factors, including 
cellular uptake, metabolic activation and detoxification.  Most ICL agents have to be 
transported into the cell and then into the nucleus.  A number of ICL agents are 
metabolically converted in the cell into an agent with a much higher activity (Wiencke and 
Wiemels 1995).  Metabolism also yields other damaging agents.  Mitomycin C, for example, 
undergoes a cycle of oxidation and reduction, thereby activating the agent and generating 
reactive oxygen species that can cause additional damage to the cell (Pritsos and Sartorelli 
1986; Tomasz 1995; Buchwald and Moustacchi 1998). Nitrogen mustard and cisplatin also 
give rise to reactive oxygen species (Clarke, Marsh et al. 1998).  On the other hand, 
metabolism also inactivates ICL agents, often via the cytochrome P450 reductase system 
(Wiencke and Wiemels 1995).  Furthermore, intracellular thiols, such as glutathione and 
metallothionein, can detoxify ICL agents (Chu 1994).  
ICL agents form a number of adducts with DNA.  These adducts are not always 
produced randomly throughout the genome, because chromatin structure can influence 
adduct formation (Vos and Wauthier 1991); (Islas, Vos et al. 1991; Larminat, Zhen et al. 
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1993).  ICLs only represent a small fraction of the adducts formed by DNA cross-linking 
agents. Nevertheless, they are thought to be the main determinant of the toxicity of ICL 
agents, due to their inhibition of DNA strand separation and, therefore, of DNA replication, 
transcription, and segregation (Islas, Vos et al. 1991; Larminat, Zhen et al. 1993; Lawley and 
Phillips 1996).   
To adequately respond to the ICLs, cells have to recognize them.  They could 
recognize the ICL itself by its distortion of the DNA helix.  However, the three-dimensional 
structures of ICLs are variable, which could influence the efficiency of ICL recognition and 
repair.  Cells could also recognize the transcription or replication block induced by the ICLs.  
Any damage response will include cell cycle arrest and, if repair fails, cell death.  
DNA Cross-Linking Agents and S100 calcium-binding protein P (S100P) 
As mentioned earlier, ICL DNA damage caused by bifunctional alkylating agents is 
implicated in the pathogenesis of therapy-related MDS and MDR-AML.  This is supported 
by the development of MDS and MDR-AML in Fanconi anemia patients and in patients 
who receive bifunctional cross-linking agent chemotherapy.  Therefore, characterizing 
mammalian cells (specifically hematopoietic cells) responses to DNA cross-link damage may 
be relevant to elucidating the molecular pathogenesis of MDS and MDR-AML.  To search 
for genes selectively involved in the cellular response to DNA cross-linking agents, HL-60 
cells were treated with bifunctional cross-linking agents.  Gene expression profiles were 
compared using cDNA microarray analysis.  To eliminate the background noise caused by 
monofunctional adducts, cells were also treated with equitoxic doses of monofuctional 
alkylating agents, Dimethylaminoethyl chloride (DME) and 2-Diethylaminoethyl chloride 
(DEE) for comparison (Figure I-1).  The comparison among non-treated HL-60 cells and 
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those treated with HN2 or DME/DEE revealed that S100P mRNA was selectively 
upregulated in bifunctional alkylating agent treated HL-60 cells but not in non-treated 
control or cells treated with monofunctional agents.  
S100P, a novel member of the S100 calcium binding protein family, present in 
human placenta, has 95 amino acid residues and shares about 50% sequence identity with 
the brain S100 proteins alpha and beta (Gribenko, Hopper et al. 2001; Sorci, Riuzzi et al. 
2003).  Unlike the rest of the family, most of which are located on chromosome 1, the 
human S100P gene is located on chromosome 4p16 (Donato 1991; Donato 1999; Donato 
2001; Donato 2003).  It has three exons, two of which encode calcium-binding domains, a 
common motif shared by the S100 calcium-binding protein family.  Like other members of 
the S100 family, dimer formation appears to be crucial for function.  S100P exists as a 
homodimer and has two functional EF hand/polypeptide chains.  The S100P dimmer 
subunit contains four helices: helix 1 (residues 3–18), helix 2 (residues 30–40), helix 3 
(residues 53–61), and helix 4 (residues 71–92).  In S100P, the two calcium-binding loops 
cross in an antiparallel manner and cross-strand hydrogen bonds between 27–28 and 68–69, 
respectively.  The hydrogen bonds between these two strands contribute to a tight 
interaction between the loops of the two EF-hands (Zhang, Wang et al. 2003).  This small 
95-amino acid protein binds divalent cations, including calcium and magnesium (Figure I-2). 
The binding has an effect on protein conformation, and in turn interaction with target 
proteins (Gribenko, Lopez et al. 1998).  
The S100 class of EF-hand calcium-binding proteins is a multigene family expressed 
exclusively in vertebrates (Donato 2003). Members of this family can be upregulated during 
cell differentiation and malignancy (Schäfer & Heizmann, 1996; Grigorian et al., 1996), 
associated with chemotaxis (Newton & Hogg, 1998; Jinquan et al., 1996), and may have 
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functions in the cell cytoskeleton and motility (Donato, 1991).  S100P was first cloned from 
placenta (Becker et al 1992), and the biological function and cellular localization of S100P 
are areas of active investigation.  S100P upregulation has been observed in a wide range of 
cancers, suggesting a relationship to initiation and development of malignancies.  S100P 
overexpression is associated with immortalization of human breast epithelial cells in vitro and 
early stages of breast cancer development in vivo (Guerreiro Da Silva, Hu et al. 2000; Mackay, 
Jones et al. 2003). The S100P protein and message are both regulated by androgens in 
prostate cancer cells, demonstrating different expression in androgen-dependent and 
androgen-independent prostate cancer cell lines (Averboukh, Liang et al. 1996).  cDNA 
microarray analysis of the CWR22 xenograft model system found S100P to be upregulated in 
prostate cancer progression.  This upregulation of RNA and protein was also seen in patient 
samples (Spyro Mousses 2002).  S100P is transiently expressed during the early stages of 
differentiation in human esophageal epithelial cells and it is overexpressed in esophageal 
cancer (Sato and Hitomi 2002; Zhi, Zhang et al. 2003).  In addition, S100P expression is 
upregulated in pancreatic cancer.  Comparisons among pancreatic adenocarcinoma, 
pancreatic cancer cell lines, normal pancreas, and chronic pancreatitis reveal that S100P gene 
is selectively expressed in the neoplastic epithelium of pancreatic adenocarcinoma (Hasel, 
Rau et al. 2001; Logsdon, Simeone et al. 2003).  In addition, the E7 oncoprotein of Human 
papillomavirus type 16 (HPV16), upregulates S100P.  HPV16 is a dominant risk factor for 
the development of cervical cancer (Hellung Schonning, Bevort et al. 2000).  Transgenically 
overexpressed exogenous S100P in NIH3T3 cells is secreted and can stimulate proliferation 
of NIH 3T3 cells (Arumugam, Simeone et al. 2003).  Although upregulation of S100P has 
been observed in many tumors, at this time the contribution of S100P to human tumor 
development and progression is unknown.   
 8
Overview of Experimental Approach 
In order to characterize the upregulation of S100P by nitrogen mustard, the 
following experiments were performed.  
In chapter II, a more global picture of this project, what questions were asked, how 
they were addressed in the experimental approach, and how the focus was narrowed onto 
S100P are described.  In chapter II, the preliminary data of this project is also included.  Cell 
cycle analysis of HL-60 cells and effects on cell growth with HN2 or DME/DEE treatment 
can be found in this chapter.  
In chapter III, the time course of S100P upregulation by HN2 in HL-60 cells was 
tested.  The relationship of HN2 dose and S100P upregulation was also examined.  To 
confirm that the induction of S100P message was also accompanied by an increase in 
protein, HL-60 cells were treated with HN2 and cell lysates were immunoblotted for S100P 
at increasing time points.  Subcellular localization of S100P protein was determined by 
immunocytochemistry microscopy.  The time course of S100P message after HN2 treatment 
was measured at a series of time points after HN2 challenge.  The HN2 dose dependency of 
S100P expression was tested with a series of HN2 doses.  Since it is reported that S100P 
could be secreted into the cell containing media, S100P protein was quantified in media 
containing HL-60 cells with and without HN2 treatment at indicated time points.   
 
In chapter IV, to test whether S100P upregulation after HN2 treatment is a cell line-
specific effect, S100P expression after HN2 treatment in hematopoietic cell lines U937 and 
K562, as well as the nonhematopoietic cell lines HBL-100 (human breast cancer epithelial 
cell line), MCF-10F (non transformed breast cell line) and Colo 320 HSR (colon cancer cell 
line) were examined. A series of HN2 dosages near the IC50 (inhibition of 50% cell growth) 
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(Sunters, Grimaldi et al. 1998) for each cell line was used, and a time course was followed if 
no difference in S100P expression was detected at varying drug doses.  S100P mRNA 
expression was tested by real time PCR. 
In chapter V, to test whether other S100 family members are upregulated by nitrogen 
mustard as well, expression of other S100 family members was tested after HN2 exposure in 
HL-60 cells.  S100 family members tested were S100B, which share 50% homology with 
S100P, S100A8 and S100Z.  S100Z is a novel member of S100 calcium binding family that 
was found to interact with S100P in the yeast two-hybrid system (Gribenko, Hopper et al. 
2001). All were tested after HN2 treatment by real time PCR in HL-60 cells at the indicated 
time points.   
In chapter VI, to determine whether induction of S100P mRNA expression is 
specific to HN2 or is a common effect of agents that cause cross-link DNA damage, S100P 
expression in HL-60 cells was tested after treatment with the cross-linking agents melphalan, 
MMC, and cisplatin.  Melphalan and nitrogen mustard are biochemically similar, and both 
belong to the mustard family.  Both cause cross-links between N7 of two guanines.  
Mitomycn C also causes cross-links between two DNA strands through a different 
mechanism.  As with other cross-linking agents, cisplatin causes both interstrand and 
intrastrand cross-links, but intrastrand cross-links are thought to be the main toxic lesion 
induced by cisplatin.   
In chapter VII, cellular response to HN2 challenge was tested.  Cell cycle and cell 
growth were measured.  A karyotype analysis was completed on 20 metaphases from HL-60 
cells exposed to HN2 for 14 d.  In this chapter, cells that were exposed to HN2 before were 
also rechallenged to test possible development of resistance to HN2.  The relationship 
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between S100P expression, cell differentiation, cell cycle distribution and cell proliferation 
was also investigated.   
In chapter VIII, the conclusions of the findings of this project are discussed, 
including the possible role of S100P in response to DNA cross-link damage such as cell 
survival, cell proliferation, anti-apoptosis, and cell migration and invasion.  Future directions 
include S100 mouse models.   
In conclusion, both S100P mRNA and protein are found to be upregulated by DNA 
cross-linking agents.  This upregulation is confirmed with different cell lines and cross-
linking agents. These findings suggest a role for S100P in the response of hematopoietic cells 
to DNA cross-linking agents.  Potential specific function of S100P in recognition of DNA 
damage, cell cycle arrest, apoptosis, DNA repair, or other functions remain to be defined. 
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Figure I-1.  Structure of bifunctional agent HN2 and monofunctional agents DME and DEE  
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Figure I-2 a. Chromosome location of S100P; b. general structure of S100 calcium binding 
protein family; c. crystal structure of S100P monomer (left) and dimer (right)(Zhang, Wang 
et al. 2003). 
c 
 13
II.  
 
INITIAL IDENTIFICATION OF DIFFERENTIALLY REGULATED GENES 
Introduction 
MDS and MDS-related AML are complicated diseases with a multiple step 
pathogenesis.  The molecular pathogenesis of these two diseases remains uncertain.  Their 
diagnosis is based on several factors including clinical history, histology, and cytogenetics, 
none of which are specific or completely sensitive.  The lack of clear understanding of the 
pathogenesis of these diseases contributes to ineffective therapies and a generally 
unfavorable prognosis for these patients.  Elderly patients are ineligible for bone marrow 
transplantation, which is the only curative therapy for MDS patients.  Unlike chronic 
myelogenous leukemia and its associated BCR-ABL fusion protein, there are currently no 
molecular targets for directed treatment of MDS and MDR-AML.  There are no animal 
models or other systemic models for the pathogenesis of MDS and MDR-AML or the 
preleukemic phenotype of MDS.  It has been proposed that MDS results from a 
combination of increased cell proliferation and increased cell death (Mundle, Iftikhar et al. 
1994).  However, this hypothesis cannot account for the hypercellular bone marrow in MDS 
and MDR-AML (Head 1996; Jin, Wang et al. 2003).  If there is increased apoptosis, the total 
number of cells will be decreased in the marrow in a short period of time.  In addition, the 
large amount of cell death should result in increased uric acid, a metabolized product of 
degradation of purines; the absence of hyperuricemia in these patients is not consistent with 
an increased amount of cell death.   
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A multiple step process involving DNA cross-link damage has been proposed for 
the pathogenesis of MDS and MDR-AML (Head 1996).  DNA cross-link damage is 
implicated in the pathogenesis of MDS and MDS related AML.  The HL-60 cell line was 
used to investigate how DNA cross-link damage may be involved in the pathogenesis of 
MDS and MDR-AML by searching for genes that respond to cross-link DNA damage.  Cells 
were exposed to the DNA cross-linking agents HN2, and the gene expression profile was 
analyzed.  Those genes that respond to DNA cross-link damage may be involved in the 
cellular response to these agents.  The cells were also treated with monofunctional alkylating 
agents (DME and DEE) for comparison, to eliminate the effect of monofunctional 
alkylation.  Dose selection is based on the MiCK (micro culture kinetic) assay (Kravtsov, 
Greer et al. 1998) and flow cytometry.  Maximal concentrations that cause minimal apoptosis 
were used, which was determined by MiCK and flow cytometry.  For HN2 the dose was 
1µM; DME was 50µM; DEE was 100µM; these doses have similar toxic effects on cells.  It 
should be noted that concentrations of DME and DEE equimolar to the HN2 
concentrations used had little toxic effect on HL-60 cells.  The doses of DME and DEE that 
were used are 50 to 100 fold greater that the HN2 dose to cause the same toxic effect. 
HL-60 cells were treated with these agents, and RNA was extracted from each 
sample at a series of time points after HN2 challenge.  Gene expression profiles were 
compared among nontreated control, the HN2 treated group, and the DME/DEE treated 
group using cDNA macroarray, PCR-select, and cDNA microarray.  These three methods 
are the most commonly used gene expression profile comparison methods; each has 
advantages and disadvantages.  Genes selectively regulated by HN2 were identified and 
subjected to further confirmation through virtual northern blot and real time PCR analysis.  
The expression of these genes was also reproduced in a separate group of experiments.  
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Multiple analyses identified S100P as a gene consistently and reproducibly upregulated by 
HN2.   
Materials and Methods 
Cell lines.  HL-60 (human acute promyelocytic leukemia) cells were obtained from 
American Type Culture Collection (Rockville, MD).  They were cultured in RPMI-1640 
medium supplemented with 10% fetal-calf serum (FCS), penicillin, and streptomycin.  Cells 
were maintained in a 37°C, 5% CO2, fully humidified incubator (using the protocols 
recommended by the supplier), passed twice weekly, and collected for experimental 
procedures when in log-phase growth (cell density 4 x 105 cells/ml). Viable cells were 
counted using trypan blue exclusion. 
Cross-linking agents and monofunctional alkylating agents.  The cross-linking 
agent analytical-grade mechlorethamine (nitrogen mustard, HN2), and the monofunctional 
alkylating agents (2-Dimethylaminoethyl chloride (DME) and 2-Diethylaminoethyl chloride 
(DEE)) were purchased from Sigma-Aldrich  (St. Louis, MO USA).  
Cell cycle analysis.  2 × 106 cells with or without challenge of alkylating agents 
were collected and fixed in 5 ml ice-cold 70% ethanol, and stored at -20°C overnight in the 
dark.  The ethanol was removed by washing with PBS, and the cells were incubated in 500 µl 
propidium iodide (0.1 mM EDTA, 0.02 mg/ml propidium iodide, 0.1% Triton X-100 in 
PBS; Sigma) for 30 minutes at room temperature in the dark.  Flow cytometric analysis of 
DNA content was then performed using a FACScan analyzer (Becton Dickinson, Mountain 
View, CA).  Cell cycle analysis was conducted using ModFit cell cycle software and WinList 
histogram software (Verity Software House, Topsham, ME).  Apoptotic cell death was 
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quantified as the proportion of cells in the population with a subdiploid (<2N) DNA 
content. 
Microculture kinetic (MiCK) assay.  The MiCK assay is an automated optical 
density based assay that detects membrane blebbing at 5 min intervals over 72 hours.  The 
MiCK assay provided both the time course and the extent of apoptosis initiated by alkylating 
agents.  The assays were completed as previously described (Kravtsov, Greer et al. 1998).  
Cells were suspended in complete medium at 2 x 105 cells/ml, plated in 240-µl aliquots in a 
96-well micro titer plate (Corning-Costar, Cambridge, MA), and incubated in a fully 
humidified atmosphere of 5% CO2 for 60 minutes.  Appropriate dilutions of HN2 were 
added to wells in 10-µl aliquots to achieve final concentrations of 0.2, 0.4, 0.6, 0.8, 1, 1.25, 
1.5 and 2 µmol/L.  After incubation at 37°C for 30 minutes in a completely humidified 
atmosphere of 5% CO2 in air, 50 µl of sterile mineral oil (Sigma, St. Louis, MO) were layered 
on the top of each microculture.  The microtiter plate was then placed in the incubation 
chamber of a spectrophotometer (SPECTRAmax 340, Molecular Devices Corp., Sunnyvale, 
CA), incubated at 37°C, and the OD at 600 nm was read every 5 minutes for a period of 72 
hours.  The reader was calibrated to zero absorbance using wells containing only complete 
medium without cells.  The extent of apoptosis was expressed as both kinetic units (KU) of 
apoptosis and percentage of apoptotic cells using methods described in the literature 
(Kravtsov, Greer et al. 1998). 
RNA extraction.  Cells in log-phase growth with and without HN2 challenge, were 
harvested from 5 ml cultures.  Total RNA was prepared using RNeasy® Mini Kits (Qiagen 
Inc. Valencia, CA) and used for virtual Northern blot and real time quantitative PCR.   
cDNA microarray.  Total RNA isolated from untreated cells or those exposed to 
HN2, DEE or DME for 1, 6, 24 or 30 hours. was used as template for labeling with cy3 or 
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cy5 and then hybridized to a human 11K cDNA microarray (Research Genetics) by the 
Vanderbilt Microarray Shared Resource (Vanderbilt University).  GenePix Pro (Axon 
Instruments, Inc.) was used to scan microarrays and perform basic analysis of arrays and 
generating lists of differentially expressed genes.  The microarray results and a description of 
the experiments in MIAME format are available at: www.vmsr.net/supl/. 
Virtual Northern blot.  A probe of the S100P gene was hybridized to a blot 
containing cDNAs proportionally amplified from total cellular RNA.  Full-length first strand 
cDNAs were generated from total RNAs of control and drug treated cells using SMARTTM 
PCR cDNA synthesis kit (BD Biosciences Clontech, Palo Alto, CA).  Double stranded 
cDNA was then amplified by long distance PCR (Clontech, Palo Alto, CA), electrophoresed 
on a 1.2% agarose gel, denatured and transferred onto Hybond N+ Membrane (Amersham, 
Arlington Heights, IL).  A clone of the S100P cDNA spotted on the microarray was 
obtained from The Vanderbilt Microarray Core. Plasmid DNA was purified using Promega 
wizard plasmid purification kit at mini-scale and partially sequenced to confirm identity.  The 
probe was excised by restriction enzyme digestion, labeled with fluorescein using ECL 
random primer labeling (Amersham, Arlington Heights, IL) and hybridized with membranes 
in Quickhyb (Stratagene, La Jolla, CA) at 60 °C for 2 hours, and washed once with 1xSSC, 
0.1%SDS; 0.5xSSC, 0.1%SDS; 0.1xSSC, 0.1%SDS for 15 minutes each at 60 °C.  Detection 
was performed by the ECL luminescence detection method (Amersham, Arlington Heights, 
IL).  A probe for G3PDH was used to normalize cDNA loading.   
Real time PCR.  Total RNA (500 ng) was used to prepare cDNA with 
SuperScript™ cDNA synthesis kit and oligo dT (Invitrogen, Carlsbad, CA USA).  The 
TaqMan® gene specific expression assay for S100P was obtained from Applied Biosystems 
(Foster City, CA USA) and reactions performed in triplicate using an ABI PRISM 7700 
 18
Sequence Detection System (Applied Biosystems).  Ribosomal 18S RNA was used as an 
internal reference standard and relative quantitation of S100P mRNA expression was 
analyzed using SDS Version 1.7 software (Applied Biosystems).  The relative Ct (threshold 
cycle number) corrected for the internal reference standard with standard deviation and 
coefficient of variation (CV) was calculated as described in ABI protocols (Applied 
Biosystems). The relative quantitation value of S100P, normalized to endogenous control 
18S rRNA and relative to a calibrator, is expressed as 2- Ct (fold), where Ct=Ct of 
target gene (S100P)-Ct of endogenous control gene (18S rRNA), and Ct= Ct of 
samples for target gene- Ct of the calibrator for the target gene.  In each case, real time 
PCR was performed three times with different RNA preparations. 
Results 
Cellular effects of alkylating agents.  HL-60 cells were treated with HN2, DME 
and DEE at the maximum tolerated dose that did not induce significant apoptotic cell death 
(defined as >5% cell death, determined by flow cytometry and MiCK assay analysis).  For 
HN2, the relevant dose was 1 µM, and for DME and DEE the dosages were 50 and 100 µΜ 
respectively (Figure II-1).   
At 24 hours after addition of 1 µM HN2, an obvious late S/G2 arrest was detected 
by flow cytometric analysis of DNA content (Figure II-2).  Over 96 hours at time points of 
48, 72 and 96 h, the cell cycle DNA distribution returned to a similar distribution to 
untreated cells (Figure II-2).   
Interestingly, cells arrest at different stages with bifunctional and monofuctional drug 
treatment.  HN2 causes late S/G2 arrest (Figure II-2) while DME and DEE cause early S 
phase arrest (Figure II-3). 
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S100P mRNA is increased in HN2 treated HL-60 cells relative to untreated 
and monofunctional agent-treated cells.  Microarray gene expression profile analysis 
revealed a 4-fold increase of S100P expression in 1µM HN2 treated HL-60 cells at 24 hours 
relative to an untreated and DME (50 µM) or DEE (100 µM) treated cells (Figure II-4).  
This upregulation was confirmed by virtual Northern blot analysis (Figure II-5), and real 
time PCR analysis (Figure II-6).  cDNA microarray consistently suggested S100P 
overexpression in HN2 treated cells relative to DME and DEE treated cells at 1, 6 and 30 
hours (Table 1).  
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Figure II-1.  Concentrations of HN2 (1µM) and DEE (100µM) that cause minimal cell death 
in HL-60 cells determined by MiCK assay. 
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Figure II-2.  Effects of 1.0 µM HN2 on HL-60 cell cycle distribution.  HL-60 cells were 
treated with HN2 over a 96 hours period.  The cell cycle distribution was assessed by 
quantitation of cellular DNA analyzed by flow cytometry.  
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Figure II-3.  S phase Cell cycle arrest in HL-60 cells induced by monofunctional agents 
DME and DEE at 24 hours, measured by flow cytometry. 
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Figure II-4.  Upregulation of S100P mRNA by HN2, but not by monofunctional alkylating 
agents DME / DEE.  Total RNA was harvested from untreated cells and those treated with 
1 µM HN2, 50 µM DME and 100 µM DEE 24 hours after treatment.  S100P mRNA level in 
each sample was measured by cDNA microarray analysis.  Y axis:  fold increase of S100P 
over control.  Error bar; standard deviation.   
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Figure II-5. Virtual Northern analysis of induced S100P mRNA by HN2 and not by 
monofunctional alkylating agents DME or DEE. The cDNA was proportionally amplified 
from total cellular RNA isolated from cells untreated and those treated with 1µM HN2, 
50µM DME or 100µM DEE for 24 h. Sample loading was adjusted for equal G3PDH signal 
intensity. S100P was specifically upregulated by HN2. 
 25
 
 
 
 
 
 
 
Figure II-6.  Real time PCR analysis of S100P in HL-60 cells treated with 1 µM HN2, 50 µM 
DME, 100 µM DEE and untreated control at 24 hours.  The error bars are CVs that were 
consistently less than 5%. 
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Table 1.  Specificity of HN2 versus monofunctional alkylating drugs (at 1, 6, and 30 hours 
after treatment) to induce S100P expression as observed in the analysis of transcript levels by 
cDNA microarray.  “-”: not determined 
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Discussion  
The pathogenesis of MDS and MDS-related AML are not understood.  There is an 
increased incidence of MDS and MDR-AML in Fanconi Anemia patients and in patients 
who undergo chemotherapy with alkylating agents and agents that cause cross-link DNA 
damage.  Fanconi Anemia patients have increased sensitivity to DNA cross-linking agents.  
These observations suggest that interstrand cross-link DNA damage plays a role in the 
pathogenesis of MDS and MDR-AML.   
To mimic the cellular response to DNA cross-linking damage, the tumor cell line 
HL-60 as treated with the cross-linking agent nitrogen mustard and analyzed gene expression 
profile changes.  Two monofunctional alkylating agents (DME and DEE) were used for 
comparison.  This strategy was employed to identify HN2-selectively-regulated genes.  A 
series of HN2 concentrations were used to identify the optimal dose to use for the 
microarray experiment.  It was found that 1 µM HN2 caused a minimal amount of apoptosis 
in HL-60 cells.  At concentrations of 1 µM and lower, HN2 causes G2 arrest in HL-60 cells.  
Similarly toxic doses for DME and DEE were also used, which are 50 µM and 100µM 
respectively.  It should be noted that 1 µM HN2 is a relatively high concentration since it can 
abrogate the PHA mediated stimulation of PBMCS culture (data not shown).  The difference 
in tolerance may be because HL-60 is a tumor cell line, while PBMCS are normal cells.  The 
lack of functional p53 in HL-60 cells may lead to increased drug tolerance in these cells, 
resulting in the need for higher doses of drugs to cause cell cycle arrest following DNA 
damage.   
Another interesting observation is that HN2 causes late S/G2 cell cycle arrest, while 
the monofunctional agents DME/DEE cause earlier S phase arrest.  The explanation may 
be that the DNA interstrand cross-links formed between two DNA strands block the 
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completion of DNA replication and mitosis.  In addition, the concentration of DME and 
DEE used was 50 to 100 times higher than HN2.  It may take relative large amount of 
monoadducts to cause similar toxic effects versus DNA cross-linking damage.  
To make the comparison between the HN2 treated, control, and monofunctional 
agents treated groups, several methods were tried before cDNA microarray analysis was 
used.  These included cDNA macroarray and PCR-select.  A macroarray plate carries much 
fewer genes than cDNA microarray, which limits its power in analysis to find candidate 
genes that respond to HN2.  PCR-select is labor intensive, takes a long time to finish one 
cycle from extracting RNA to obtain a list of candidate genes, and has a high false positive 
rate making reproducibility difficult.  Technically, these two methods are time consuming 
and costly.  
Microarray analysis provides information about a large number of genes and allows 
detailed statistical analysis for gene selection.  It takes a shorter period of time for each cycle 
of search.  The combination of these features allowed the development of a list of genes that 
had a high probability of being specifically regulated by HN2.  A disadvantage of this 
approach for this experiment is the disparity of labeling efficiency.  For example, when 
comparison between the control and HN2 treated HL-60 cells was made, the RNA from the 
latter group is not as intact as the control group RNA.  In addition, HN2 can interact with 
RNA.  This results in different labeling of sample and control with cy5 and cy3 in the 
microarray analysis.  To avoid this problem, for each group of experiments reverse labeling 
and comparison (A vs B and B vs A) was done.  Only those genes that consistently appeared 
in those two comparisons were considered as candidate genes.  These genes may have 
potential diagnostic value in the future and also may provide targets for additional 
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investigations into the cellular mechanisms of MDS and MDR-AML.  This research was 
focused on genes that were reproducibly altered by HN2. 
S100P was found to be selectively upregulated by HN2 compared to control and 
monofunctional agent-treated groups.  Its upregulation was reproducible and confirmed 
through several methods.  The upregulation of S100P after HN2 exposure suggests that it 
plays a role in the response to DNA cross-link damage.  S100P is one of the least studied 
genes of the S100 calcium binding protein family.  Current publications link its 
overexpression to tumor initiation and progression (Amler, Agus et al. 2000; Guerreiro Da 
Silva, Hu et al. 2000).  Along with other S100 proteins, S100P is exclusively expressed in 
vertebrates (Kretsinger 1976).  Selective high expression of S100P in bone marrow, the 
calcium binding property of S100P, and evolution of S100P in vertebrates suggest S100P 
expression may have evolved in parallel with the migration of hematopoiesis to its 
intramedullary location.  The previous findings plus the upregulation of S100P by HN2 and 
other cross-linking agents in marrow cell lines suggest parallels to the Fanconi protein 
system, a system that is also exclusively expressed in vertebrates and is involved in the 
cellular response to cross-link DNA damage.  The FA protein system also serves an 
unknown but critical protective role in marrow and bone as evidenced by bone and bone 
marrow abnormalities in FA. 
Other interesting genes were identified, but for most regulation by HN2 was difficult 
to reproduce.  It is possible that the asynchronous culture of HL-60 cells was a problem.  
During the experiment, the cells that are exposed to the cross-linking agents are at different 
points in the cell cycle.  This may result in different gene expression response patterns in 
different cells during each experiment. One way to avoid this would be to synchronize the 
cells.  Another way is to sort different cell cycle populations and compare cells from 
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different samples that are at the same cell cycle stage, or compare different cell cycle stages, 
in the same sample.  For example, the G2 population of non-treated HL-60 cells and HN2 
treated HL-60 cells at 24 hours after treatment could be sorted, and a microarray to compare 
gene expression patterns could be performed.  Alternatively, elutriation has been used to 
isolate cells in specific phases of the cell cycle.  However, since S100P was a gene of interest, 
the alternatives were not pursued. 
With these findings, it was asked, is this S100P response unique to the HL-60 cell 
line?  Is it unique to HN2?  Do other cross-linking agents upregulate S100P?  Is it unique to 
S100P? Do other S100-calcium binding family members respond the same way to drug 
challenge? Does the S100P protein expression respond to HN2 treatment? Where is the 
S100P protein localized, and is it secreted?  In the next few chapters, these questions were 
addressed.   
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III.  
 
CORRELATION BETWEEN INDUCTION OF mRNA AND INDUCTION OF 
S100P PROTEIN   
Introduction 
S100P mRNA is selectively upregulated by 1 µM nitrogen mustard (HN2) at 24 hours 
after drug challenge.  In order to observe the kinetics of the upregulation, S100P expression 
at multiple time points after HN2 exposure by real time PCR amplification was tested.  The 
effect of varying doses of HN2 on the expression of S100P was also examined. 
In the preliminary data, the upregulation of S100P mRNA level by HN2 was 
identified through microarray analysis, and confirmed by virtual northern blots and real time 
PCR data.  Because RNA expression may not correlate with protein expression, to evaluate 
the S100P protein response to HN2, we tested S100P protein expresssion by Western blot at 
series of time points.  To explore the possible physiological role of S100P, the cell cycle 
distribution of S100P protein expression was analyzed by flow cytometry, quantitating S100P 
protein versus DNA content.  This was used to determine S100P protein intracellular levels, 
confirming Western blot data.   
The subcellular localization of S100P protein in hematopoietic cell lines has not been 
previously described and may provide insight to the function of S100P and its role in the 
response to DNA cross-link damage.  Immunocytochemistry (ICC) was used to detect the 
localization of S100P protein in HL-60 cells and to observe cellular levels of S100P over 
time.  Possible changes in S100P subcellular location of S100P after HN2 challenge was also 
examined by immunocytochemistry.  Some proteins in the S100 family are secreted by cells. 
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It has also been reported that S100P is secreted into media when expression is transgenically 
induced in NIH3T3 cells, which do not otherwise express S100P (Arumugam, Simeone et al. 
2004).  It is unknown whether S100P is secreted into media by HL-60 cells.  If it is, it will be 
important to know if this secretion is regulated by HN2 in HL-60.cells, which do express 
S100P, in the presence or absence of HN2 treatment.  Therefore, we also analyzed HL-60 
containing media for evidence of S100P secretion. 
Materials and Methods 
Cell lines.  As described previously.   
Cross-linking agents and monofunctional alkylating agents.  As described 
previously.   
RNA extraction.  As described previously.   
Real time PCR.  As described previously.   
Protein extraction.  HL-60 cells were treated with 1 µM HN2, and proteins were 
extracted at specified time points.  The cells were washed in phosphate-buffered saline (PBS) 
and lysed in sample buffer (20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol) 
(Sigma), and then homogenized with a polytron homogenizer (6000 rpm) with a protease 
inhibitor cocktail (Complete TM) (Roche, Nutley, NJ). Protein extracts were centrifuged for 
15 min at 4 °C at 12,000 rpm in an Eppendorf centrifuge, and the supernatants were used 
for Western blot analysis. Protein concentration was estimated by the Bradford procedure 
(Bio-Rad, Hercules , CA ) with bovine serum albumin as a standard. 
Antibodies.  Anti-S100P primary monoclonal mouse antibody was purchased from 
BD Biosciences (Transduction Laboratories, Lexington, KY).   
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Western blot.  Whole cell protein extracts (25 µg) were electrophoretically separated 
on 15% SDS gels and transferred to PVDF membranes (Millipore Corporation, Billerica, 
MA).  The blot was blocked for non-specific protein binding and probed with an anti-S100P 
primary monoclonal mouse antibody (1:100) (BD Transduction Laboratories, Lexington, KY 
USA).  Antibody binding was detected using an HRP-conjugated goat anti-mouse IgG 
(1:4000)(Jackson Immuno Research Lab. Inc., West Grove PA USA).  The antibody 
interaction was visualized by ECL detection (Amersham, San Francisco, CA, USA).  Human 
placental lysates were used as a positive control (Transduction Laboratories, Lexington, KY 
USA). 
Immunocytochemistry.  Slides of HL-60 cells were prepared by cytocentrifugation. 
After air drying cells were fixed and endogenous peroxidase activity quenched in methanol 
with 3% H2O2 at room temperature for 10 min. Cells were hydrated through gradient 
alcohols to phosphate buffered saline (PBS). Nonspecific protein binding sites were blocked 
with 1% bovine serum albumin, 10% bovine calf serum in PBS for 30 min. The slides were 
exposed to a monoclonal anti-S100P antibody (Transduction Laboratories) diluted 1:15 in 
blocking solution for 18 h. at room temperature. An avidin-biotin-peroxidase complex 
(Vector Laboratories, Inc., Burlingame, CA) based detection system was used to visualize the 
antibody interaction. Reagent control slides were included in each experiment as well as an 
isotype control antibody. 
Quantitation of S100P protein by flow cytometry.  Cellular S100P content was 
measured in HL-60 cells from 0 to 96 hours after 1 µM HN2 treatment.  Cells were washed 
twice in PBS +2% FCS and fixed in 70% EtOH in the dark at room temperature for 1 hour.  
Cells were then washed twice in cold 1X PBS.  A saturating amount (as determined by 
titration on HL-60 cells) of S100P antibody was added and allowed to incubate in the dark at 
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room temp for 1 hour.  A matching concentration IgG1-Isotype tube was also prepared in 
the same fashion.  Cells were washed twice in PBS + 2% FCS.  A FITC-labeled IgG1-goat 
anti-mouse antibody at 1 µg/µl was added to S100P and isotype tubes and incubated for 1 
hour.  Cellular DNA was stained with 7-AAD.  An FC500 cytometer (Beckman-Coulter) 
with a 488 nm and 633 nm excitation source was used for data acquisition.  S100P data were 
analyzed using WinList 5.0, ModFit LT 5.0 (Verity Software House, Topsham, ME) and 
Excel 5.0 (Microsoft, Seattle WA).  S100P expression was determined by comparison of each 
time point to the background protein expression as determined by the isotype control in 
drug treated and control samples.  This method was also used to measure the frequency and 
intensity of S100P expression in each cell cycle state.  Cell cycle data was determined by 
modeling in ModFit LT and analyzed using Lysys software (Becton Dickinson). 
Quantitation of MPM2 protein by flow cytometry.  Please refer the above 
paragraph for details of the methods.  MPM2 antibody was provided from Esoterix 
(Brentwood, TN). 
ELISA for S100P.  S100P was quantified in the media collected from 1 µM HN2 
treated cells at specified time points after HN2 treatment.  The media was collected and 
concentrated using YM10 centricon concentrating filters. (Millipore, Billerica, Mass.,USA,)  
Concentrated samples (100 µl) were incubated for 2 hours at room temperature in antibody 
coated plates and washed thrice with wash buffer.  S100P was captured between an anti-
bovine S100 calcium-binding protein B (S100B) rabbit polyclonal antibody (Abcam 
Ltd.,Cambridge, UK) and an S100P specific monoclonal antibody, using an ELISA kit 
(Protein Detector ELISA kit, KPL, Gaithersburg, Maryland, USA).  Bound S100P was 
detected with a horseradish peroxidase (HRP) labeled anti-rabbit secondary antibody and 
using tetramethylbenzidine (TMB) substrate.  Color development was blocked with 1M 
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phosphoric acid and read at 450nm.  S100P in a placental lysate was used as a positive 
control, and media with or without serum were used as negative controls. 
Results 
Time course of S100P mRNA induction by HN2.  HL-60 cells were treated with 
1 µM HN2, total RNA was extracted after 1, 2, 6, 24, 48, and 72 hours, and relative 
quantification of RNA by real-time PCR was performed.  Human placental RNA was used 
as a positive control for S100P amplification.  S100P mRNA was not measurably 
upregulated at early time points (1, 2, and 6 hours after treatment), but increased 2.3 fold 
over baseline at 24 hours, 8.3 fold at 48 hours and 76.4-fold at 72 hours after HN2 challenge 
(Figure III-1).  
The increase in S100P mRNA levels is HN2 dose-dependent.  To determine if 
the observed increase in S100P mRNA levels is HN2 dose-dependent, HL-60 cells were 
treated with 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, and 5 µM HN2, and total RNA extracted 24 hours 
after treatment. Real-time PCR revealed that S100P mRNA was progressively upregulated 
from 2-fold at 0.25 µM to 10-fold at 2.5 µM over baseline (Figure III-2).  At 3 and 4 µM 
HN2, the expression level of S100P drops; at these doses, there is a significant amount of cell 
death.  The HL-60 cell culture was almost destroyed by 5 µM HN2. 
S100P protein levels are upregulated with HN2 treatment.  To confirm that the 
induction of S100P message was also accompanied by an increase in protein, HL-60 cells 
were treated with 1µM HN2 and cell lysates were immunoblotted for S100P at the indicated 
time points (Figure III-3).  Placental lysates were used as a positive control.  S100P protein 
levels in HL-60 cells are undetectable in untreated cells as well as cells at 2, 24, (not shown) 
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45 and 70 hours after treatment.  S100P protein was strongly induced at 90 hours post 
treatment with HN2 (Figure III-3 A). 
Flow cytometry for S100P and cell cycle analysis.  A subpopulation of cells with 
G2/4N DNA content expressed a high level of S100P at 96 hours after HN2 (Figure III-3 
B).  An increasing number of cells with elevated S100P were observed at 96 hours with 
increasing levels of HN2 (Figure III-3C).  The elevated level of S100P expression detected by 
flow cytometry in a subset of cells at 96 hours (Figure III-3B and C) appeared to correlate 
with immunoblot detection of S100P at approximately the same time after adding HN2 
(Figure III-3A). 
S100P protein subcellular localization.  Immunoperoxidase localization of S100P 
in untreated HL-60 cells showed an occasional positive cell with low level of expression 
within cytoplasm only (Figure III-4A).  Immunoperoxidase analysis of S100P at 24 hours 
after HN2 showed a few weak positive staining cells (Figure III-4B).  An increased number 
of more reactive cells (Figure III-4 C) were detected at 96 hours after HN2.  These reactive 
cells appear to coincide with the detection of a subset of G2/4N cells with high level of 
immunoreactivity by flow cytometry (Figure III-4B and C).  At 192 hours after HN2, a large 
number of reactive cells were detected (Figure III-4D). 
The immunocytochemical analyses consistently showed cytoplasmic reactivity only, 
indicating that HN2 did not alter S100P intracellular localization.  In addition, mitotic cells in 
cultures untreated or treated with HN2 showed a low level or no S100P immunoreactivity. 
HL-60 cells treated with DME (50 µM) for 96 hours showed the same rare weak 
S100P reactive cells as with untreated cells (data not shown).  The results were consistent 
with the specificity of HN2 versus monofunctional alkylating drug to induce S100P mRNA 
upregulation. 
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S100P is not secreted by HL-60 cells before or after HN2 treatment.  A 
sandwich ELISA was used to examine the extracellular S100P levels in HL-60 cell cultures.  
No detectable levels of S100P were observed in medium from HL-60 cells untreated or 
treated with HN2 for 96 hours (data not shown).  Placental lysate containing S100P was used 
as a positive control.  The baseline level of S100P in the media containing HL-60 cells 
without drug treatment was very close to negative control levels.  S100P levels in the media 
at 24, 48, 72, and 96 hours after HN2 treatment did not change significantly, indicating that a 
measurable amount of S100P protein is not secreted by HL-60 cells into media before or 
after HN2 treatment.   
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Discussion 
S100P mRNA was found to be selectively upregulated by HN2 but not by 
monofunctional alkylating agents.  To characterize these findings, the kinetics of S100P 
upregulation by HN2 was analyzed.  At 1 µM HN2, the upregulation of S100P mRNA is 
continuous during the time points assayed.  The mRNA increase starts at 24 hours and 
increases dramatically by 72 hours.  These findings suggest S100P upregulation is not 
transient.  The underlying mechanism remains uncertain. 
S100P upregulation is HN2 dose dependent.  DNA damage increases with increasing 
HN2 doses and thus the dose dependency of S100P suggests it may have a role in response 
to DNA damage, but its potential role is unclear.   
S100P protein increases also, but is delayed versus the mRNA response.  In HL-60 
cells with no drug challenge, S100P protein was hardly detectable by Western blot, and no 
change was detected in protein expression up to 72 hours, but S100P was strongly induced 
by 90 hours after 1 µM HN2 treatment.  S100P mRNA expression is tissue specific (Jin, 
Wang et al. 2003), and S100P mRNA level is very high in HL-60 cells compared to other 
tissue and cell lines.  However, S100P protein is expressed only at very low levels at baseline, 
and there is a lag between mRNA overexpression and S100P protein increase.  Flow 
cytometry also confirmed the upregulation of S100P protein; and interestingly, a 
subpopulation of cells in G2 expresses very high levels of S100P protein after treatment.   
Immunocytochemistry revealed at 96 hours, a group of cells with strong cytoplasmic 
staining of S100P (Figure III-4); this subset of cells has a unique morphology type. S100P 
appeared to localize in the cytoplasm of HL-60 cells.   These cells were larger than most 
cells, with kidney bean shape nuclei, and with a big negative staining cytoplasm area adjacent 
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to nuclei, and appearing to represent the Golgi apparatus.  These cells may correspond to the 
S100P protein detection in the Western blot.  Characterizing this group of cells may help to 
illuminate the function of S100P.  Cell cycle arrest in G2 occurs around 24 hours; is largely 
gone by 48 hours, and at 96 hours, the cell cycle distribution of HL-60 cells is similar again 
to normal cells (Figure II-2).   
S100P protein overexpression occurs at 96 hours, as opposed to G2 cell cycle arrest 
at 24 hours.  There is no significant subG1 population throughout the first four days of the 
time course.  Given these findings, S100P is unlikely to be directly involved in the G2 cell 
cycle arrest or cell death.  The possible role of the upregulation at later time points includes 
promotion of cell survival through overcoming G2 cell cycle arrest.  The regulation of S100P 
protein with the cell cycle suggests a G2-M transition function, but underlying mechanism 
remains unclear.  More discussion on this topic is found in Chapter VII.   
The subcellular localization of S100P in the cytoplasm in HL-60 cells is reported for 
the first time here.  No obvious relocalization was found in HN2 treated HL-60 cells versus 
resting cells.  Cytoplasmic localization may provide clues to the function of S100P.  For 
example, the non-nuclear localization of S100P indicates that it does not have a direct role as 
a transcriptional regulatory factor, a direct role in DNA repair, or recognition of DNA 
damage.   
Some members of the S100 calcium-binding protein family are secreted into the 
media (Donato 2001).  It was recently reported that S100P is secreted into media by S100P 
transfected NIH3T3 cells (Arumugam, Simeone et al. 2003).  We were unable to 
demonstrate secretion of S100P protein in HL-60 cell containing media, either with or 
without HN2 treatment.  The difference in cell types may account for these different results; 
HL-60 cells are a human hematopoietic tumor cell line, while NIH3T3 cells are non-
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transformed mouse fibroblast cells.  In addition, while HL-60 cells express S100P normally, 
it is not normally expressed in NIH3T3 cells.  It is possible that the overexpression of S100P 
in a normally non-expressing cell line may have resulted in non-physiologic secretion into 
media.  It should also be noted that S100P does not contain a classic signal peptide for 
secretion.  Lack of signal peptide may suggest S100P is not secretive protein although many 
members of S100 family are secreted without signal peptide.  Also, ICC showed no apparent 
localization of S100P protein in Golgi apparatus, given the empty paranuclear area without 
S100P staining in the cytoplasm in HL-60 cells, while many secreted proteins are localized in 
Golgi before they are secreted.  . 
In summary, upregulation by HN2 is both time and dose dependent.  Both S100P 
mRNA and protein levels are overexpressed after drug challenge wth a lag in protein versus 
mRNA expression.  After HN2 exposure, S100P protein expression is high in a subset of G2 
cells, suggesting cell cycle regulatory role for S100P.  S100P protein secretion is not detected 
with and without HN2 treatment by “sandwich ELISA”.   
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Figure III-1.  Upregulation of S100P mRNA by HN2 in HL-60 cells is time dependent. a. 
Raw data Real time PCR quantitation of S100P time course.  Total RNA was isolated at 
serial time points (0, 1, 2, 6, 24, 48, 72 hours) after 1 µM HN2 challenge from HL-60 cells, 
and used for real time PCR amplification. Each plot represents an amplification curve.  ∆Rn: 
Normalized reporter signal.  b. Data analysis of real time PCR. The error bars are CVs that 
were consistently less than 5%.  
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Figure III-2.  Upregulation of S100P mRNA by HN2 in HL-60 cells is dose dependent at 24 
hours.  Total RNA isolated from HL-60 cells after challenge with serial HN2 doses (0, 0.25, 
0.5, 1, 1.5, 2, 2.5, 3, 4 µM) was used for real time PCR amplification. The error bars are CVs 
that were consistently less than 5%. 
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Figure III-3.  Upregulation of S100P protein/antigen in HL-60 cells following addition of 
HN2.  A.  Immunoblot detection of S100P (upper panel) in whole cell protein extracts 
prepared from untreated cells (lane 1) and cells treated for 45 (lane 2), 70 (lane 3) and 90 
hours (lane 4).  The internal control beta-actin signal for the same samples (lower panel). B. 
Flow cytometric analysis of S100P and DNA of untreated (control) and cells exposed for 24 
and 96 hours to 1.0 µM HN2. C. Flow cytometric analysis of S100P and DNA in untreated 
HL-60 cells (upper panel) and cells exposed to 0.8, 1.0 and 1.2 µM HN2 (lower three panels) 
for 96 h.  In both B. and C. the panels on the right show S100P levels with increases (right 
shoulder) at 96 hours (lower right panel in B.) and with 0.8, 1.0 and 1.2 µM HN2 (lower right 
panels in C). 
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Figure III-4.  Immunocytochemical detection of S100P in HL-60 cells exposed to HN2. 
Untreated cells (A), and cells exposed to 1.0 µM HN2 for 24 (B), 96 (C) and 192 (D) h.  The 
immunoperoxidase reactivity shows a cytoplasmic localization. Original magnification: 400X. 
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IV.   
 
S100P mRNA REGULATION IN RESPONSE TO HN2 CHALLENGE IN 
OTHER TUMOR CELL LINES 
Introduction 
To determine if S100P upregulation with HN2 treatment is specific for HL-60 cells 
or is a general response in cell lines, S100P expression in MCF-10F was tested, a breast cell 
line, with HN2 treatment.  The MCF-10F cell line is a non-tumorigenic epithelial cell line.  It 
retains all the characteristics of normal epithelium in vitro, including anchorage dependence, 
non-invasiveness and non-tumorigenicity in nude mice (Soule, Maloney et al. 1990).  The 
response of S100P in these cells may closely represent the responses in normal epithelial 
cells.   
Two non-hematopoietic tumor cell lines, HBL-100 (breast cancer) cells and Colo 320 
HSR (colon cancer) cells were also tested.  S100P has been reported to be differentially 
expressed among normal breast tissue and breast cancer cell lines.  A colon cancer cell line 
was chosen because S100P is expressed in normal colon tissue, though the expression level 
is low.  In addition, there is a report showing S100P overexpression in ulcerative colitis, a 
condition that predisposes to development of colon cancer (Lawrance, Fiocchi et al. 2001).   
Two other hematopoietic cell lines that were also tested, U-937 and K562.  The U-
937 cell line is a monocytic myeloid cell line, derived from cells obtained from the pleural 
effusion of a patient with a histiocytic malignancy (Kong, Miwa et al. 1990).  As a monocytic 
cell line, it was chosen to represent myeloid cell lines. K562 cells (chronic myeloid leukemia 
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with the translocation BCR-ABL) (Boldt, Kopecky et al. 1994) were also used to represent 
more primitive and multipotent hematopoietic tumor cell lines. 
Different cell lines have different sensitivities to HN2.  There is published 
information on the IC50 for HN2 in the above cell lines (Sunters, Grimaldi et al. 1998).  A 
wide range of doses covering the IC50 to treat cells was used, to ensure including a dose 
having toxicity similar to a 1µM dose in HL-60 cells, and to determine HN2 dose 
dependency of S100P expression in other cell lines.  S100P expression at a series of time 
points was also followed after HN2 challenge, if varying dosage failed to show a difference in 
expression.   
Materials and Methods 
Cell lines. K562 (human chronic myeloid leukemia), U937 (human acute monocytic 
leukemia) cells, MCF-10F (nontransformed breast cell line) cells, HBL-100 (breast cancer) 
cells, and Colo 320 HSR (colon cancer) cells were purchased from American Type Culture 
Collection (Rockville, MD).  They were cultured and maintained as instructed. , They were 
passed twice weekly, and prepared for experimental procedures when in log-phase growth 
(cell density 4 x 105 cells/ml). 
Results 
S100P is induced by HN2 in U937 and Colo 320 HSR cells.  The myeloid cell 
lines U937 (human monocytic leukemia), K562 (chronic myeloid leukemia), MCF-10F 
(nontransformed breast cell line), nonhematopoietic cell lines HBL-100 (breast cancer), and 
Colo 320 HSR (colon cancer) were tested.  For each cell line, HN2 concentrations including 
the published IC50 were used, and total RNA was extracted at the indicated time points after 
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treatment.  The expression of S100P mRNA at baseline was constitutively high in both U937 
cells and K562 cells, very close to the placental control level and hematopoietic cells.  In 
K562 cells S100P mRNA did not increase after HN2 treatment at any of the time points 
tested (Figure IV-1a, Figure IV-2).  In U937 cells, the IC50 of HN2 was 4.1 µM.  S100P 
mRNA levels increased 2.2 and 3.9-fold at 51 and 74 hours after 3 µM HN2 challenge in 
U937 cells (Figure IV-2).   
S100P baseline levels in HBL-100 and Colo 320 HSR were relatively low compared 
to the placental control (Figure IV-1.b).  In Colo 320 HSR cells, at HN2 concentrations of 
0.25, 0.5, 0.75, 1, 2, and 3 µM, S100P mRNA levels increased 2, 5, 6, 6, 15, and 16.5-fold, 
respectively at 24 hours (Figure IV-1 b, Figure IV-2).  S100P message was not induced in 
HBL-100 cells with similarly toxic HN2 doses at series of time points.  HN2 did not alter 
S100P mRNA in MCF-10F (data not shown) (less than a 2 fold change).  
It is concluded that S100P induction by HN2 is not a uniform feature of cell lines, 
but is not limited to HL-60 cells, and that high expression of S100P is characteristic of 
hematopoietic cell lines. 
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Figure IV-1.  S100P mRNA expression in K562 and colo 320 with HN2 challenge.  Total 
RNA was extracted and S100P mRNA was measured by real time PCR.  S100P mRNA is 
not upregulated by HN2 in K562 cells (a); S100P is upregulated progressively in colo HSR 
320 cells with varying doses of HN2 (0.25, 0.5, 0.75, 1, 2, 3 µM)(b).  Representative 
amplification plots of real time quantification of S100P in different cell lines.  Each includes 
a plot of the positive placenta control on the left in each figure.  ∆Rn: normalized reporter 
signal. 
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Figure IV-2.  S100P is not upregulated in K562 cells with HN2 treatment at 24 hours; it is up 
regulated by 3µM HN2 at 51 and 74 hours;  it is upregulated in Colo 320 HSR by HN2 at 
various  doses. At 24 hours. 
 50
Discussion 
The goal of this specific aim is to determine if the upregulation of S100P is restricted 
to HL-60 cells.  High baseline S100P expression in the hematopoietic cell lines U937 and 
K562 was observed.  In HL-60 cells, its expression level is intermediate, while the highest 
level of S100P expression is found in placenta.  In nonhematopoietic cells such as Colo320 
HSR, MCF-10F and HBL-100, endogenous S100P expression is low.  This is consistent with 
the previously published description that expression of many S100 calcium-binding proteins 
is tissue and cell-type specific (Donato 2003).  S100P is highly expressed in hematopoietic 
cells, but also expressed in breast, prostate, esophagus and other organs (Jin, Wang et al. 
2003).  Upregulated S100P expression has been reported in breast, prostate, esophageal and 
gastric cancers.  S100P is more highly expressed in HL-60 cells and hematopoietic cells.   
It was found S100P was also upregulated by HN2 in U937 and Colo 320 HSR cells.  
As mentioned earlier, S100P has a high basal level in HL-60 cells while Colo 320 HSR cells 
have a lower basal level of S100P expression.  This indicates the upregulation of S100P by 
HN2 is not dependent on basal S100P level.  The upregulation of S100P by HN2 is not 
restricted to HL-60 cells, though the upregulation is not observed in every cell line tested.  
The underlying mechanism and role of this upregulation remains an area of investigation. 
It is not surprising to see S100P upregulation in Colo 320 HSR cells, as S100P 
mRNA is detected in normal colon tissues (Jin, Wang et al. 2003).  Using microarray, genes 
that are uniquely expressed in Ulcerative Colitis (UC) have been reported; S100P is among 
the genes that are overexpressed in colon tissue in UC, and UC is a premalignant disease 
with a high late incidence of colon cancer (Lawrance, Fiocchi et al. 2001).  S100P is not 
upregulated in K562 cells treated with HN2.  It is possible that BCR-ABL protein in K562 
may result in activation of different pathways than other cell lines in response to DNA 
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cross-link damage, not involving S100P.  Alternatively, the high level of constitutive 
expression of S100P in K562 cells may make upregulation of S100P unnecessary in response 
to DNA cross-link damage.  There is also no upregulation of S100P detected in HBL-100 
cells.   
S100P is not upregulated by HN2 in MCF-10F cells by HN2 treatment.  MCF-10F is 
a non-transformed breast cells.  It may have an adequate DNA cross-link damage 
response/repair system without S100P involvement.  In addition, epithelial cells may have a 
different DNA cross-link repair system.  However, detailed information of the system is 
largely unknown.  Fanconi patients with genetic defects in DNA cross-link repair, do not 
have epithelial cell manifestations while they develop bone marrow failure such as MDS and 
AML (Auerbach 1992; Lensch, Tischkowitz et al. 2003).  Thus cell type may contribute to 
the different response in different cell lines. 
In summary, S100P upregulation by HN2 is not limited to HL-60 cells, S100P 
upregulation by HN2 was observed in hematopoietic such as HL-60 and U937 cells as well as 
non hematopoietic cell lines such as Colo 320 HSR.  This suggests S100P may be involved in 
a relative common pathway of response to DNA cross-linking agents.  However S100P 
upregulation was not observed in all the cell lines we tested.  This suggests there may be 
multiple DNA repair systems are involved in the response to DNA cross-link damage.  
These different pathways may be tissue specific and they may complement each other.  
Different pattern activation and inactivation of certain oncogenes and tumor suppressor 
genes may affect these pathways to different degrees.  This may explain the difference of 
S100P upregulation by HN2 in these cell lines.  For example, S100P upregulation is observed 
in HL-60 and U937 cells while there is no upregulation in K562 cells.  HL-60 cells are p53 
deficient while K562 cells are BCR-ABL positive.  Their difference in carcinogenesis and 
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gene expression profile may explain their difference in response to DNA damage.  Since 
S100P upregulation is not restricted t HL-60 cells, the upregualtion carries importance in 
understanding the mammalian cell response to DNA cross-link damage.  
 53
V.   
 
RESPONSE OF OTHER S100 GENE EXPRESSIONS TO HN2 CHALLENGE   
Introduction  
S100P is upregulated in nitrogen mustard treated HL-60 cells.  The S100 calcium-
binding protein family has 21 members to date (Donato 2003).  Gene specific sequences for 
nine members of S100 calcium binding protein family including S100P are also on the 
microarray membrane.  Gene expression of the other eight S100 proteins (S100 A2, A3, A8, 
A10, A11, A12, A13, B) was not regulated by HN2 treatment based on microarray analysis.  
To further determine if S100P is unique among S100 proteins in being upregulated by 
nitrogen mustard, S100B, S100A8, and S100Z genes were analyzed. 
S100B shares more than 50% sequence with S100P (Nowotny, Spiechowicz et al. 
2003).  S100B has been reported to be expressed in neurons and may play a role in 
Alzheimer disease (Mrak and Griffinbc 2001) (Figure V-1).  Patients with Down’s syndrome 
may develop Alzheimer disease if they survive through adulthood.  They can also develop 
AML.  Thus, it would be interesting to test if S100B is also upregulated by HN2.  
S100A8, another member of S100 protein family, was also tested.  S100A8 and 
S100A9 expression in monocytes occurs in early stages of differentiation (Lagasse and Clerc 
1988) and in infiltrating monocytes, but not in differentiated tissue macrophages (Zwadlo, 
Bruggen et al. 1988), suggesting that the expression of S100A8 and S100A9 may be related 
to differentiation stages of monocytes and macrophages.  S100A8 has relative high 
expression in HL-60 cells (Figure V-2).  It has been demonstrated that S100A8 may be 
involved in inflammation (Passey, Xu et al. 1999). 
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Finally, S100Z was tested, a novel family member of the S100 calcium binding 
protein family (Donato 2003).  It was found to interact with S100P by the yeast two-hybrid 
screen (Gribenko, Hopper et al. 2001), suggesting  S100P and S100Z may form 
heterodimers, making S100Z an additional candidate for regulation by HN2.  If S100Z is not 
upregulated by HN2, it is still possible it works with S100P as a dimer that is regulated by 
HN2 induced damage.   
Materials and Methods 
Cell lines, Cross-linking agents and monofunctional alkylating agents, RNA 
extraction, and Real time PCR are as described in previous chapters. 
Results 
It was found S100B has no message expression in HL-60 cells untreated or treated 
with 1µM HN2 (data not shown).  The tissue distribution of S100B and S100P are shown 
respectively (Figure V-1, Figure V-4).  These findings indicate HL-60 cells do not express 
S100B, which is consistent with literature findings, nor is S100B inducible in HL-60 cells by 
HN2.   
Unlike S100P and S100Z, the S100A8 mRNA level was lower in placenta than in 
HL-60 cells.  The expression of S100A8 wais not regulated by 1 µM HN2 treatment at 
different time points (data not shown).  S100A8 expression was also tested in HL-60 cells 
with exposure to varying HN2 doses of 0.25, 1, 1.5, 2, and 2.5 µM HN2.  Total RNA was 
extracted at 24 hours after HN2 treatment, and the levels of S100A8 mRNA determined by 
real time PCR.  S100A8 expression was unchanged in each sample relative to the control 
(Figure V-3).   
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Finally, S100Z mRNA was analyzed in HL-60 cells that were treated with 1µM HN2 
to determine if S100Z is upregulated by HN2 treatment.  Total RNA was extracted at 1, 2, 6, 
24, 48, and 72 hours after treatment, and quantification of S100Z was performed by real-
time PCR.  Placenta, which expresses higher levels of S100Z relative to HL-60 cells, was 
used as a positive control, though the baseline S100Z expression is much lower than S100P 
in placenta.  After HN2 challenge, S100Z mRNA levels increased 2.4-fold over baseline at 6 
hours, and increased to 8-fold over baseline at 72 hours (Figure V-5).   
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Figure V-1.  S100B tissue distribution. (http://expression.gnf.org/cgi-bin/index.cgi#Q) 
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Figure V-2.  S100A8 tissue distribution. (http://expression.gnf.org/cgi-bin/index.cgi#Q) 
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Figure V-3.  S100A8 mRNA is not upregulated by HN2 challenge.  Total RNA isolated from 
HL-60 cells after serial HN2 dose (0, 0.25, 1, 1.5, 2, 2.5 µM) challenge at 24  hours.  S100A8 
mRNA level was measured by real time PCR amplification. 
a 
b 
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Figure V-4.  S100P tissue distribution. (http://expression.gnf.org/cgi-bin/index.cgi#Q) 
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Figure V-5.  Upregulation of S100Z mRNA by HN2 and time dependence. a. At serial time 
points (0, 1, 2, 6, 24, 48, 72 hours) after 1 µM HN2 challenge of HL-60 cells total RNA was 
used for S100Z real time PCR amplification. Each plot represents an amplification curve. b. 
Data analysis of real time PCR.. The error bars are CVs that were consistently less than 5%.   
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Discussion 
The S100 calcium-binding protein family contains 21 members to date.  Most S100 
calcium-binding proteins are located on chromosome 1.  S100P and S100B are located on 
chromosome 4 and 21, respectively.  Most S100 family proteins function in signal 
transduction (Donato 2001).  Deregulated expression of the genes is found in various 
cancers.  S100P is one of the least studied protein of this family, and its function is 
unknown.  Since we have demonstrated S100P is upregulated after exposure to HN2, we 
evaluated other S100 family members’ responses to HN2 challenge.   
S100B has 50% sequence identity with human S100P,.  S100B forms homodimers 
similar to S100P.  In addition to Ca2+, S100B also binds Zn2+ with a binding affinity that is 
considerably higher than that for Ca2+ (Donato 2001; Mrak and Griffinbc 2001; Sorci, Riuzzi 
et al. 2003).  S100B expression is deregulated in the cerebro-spinal fluid in Alzheimer 
Disease patients, and it has been hypothesized that it may be involved in the pathogenesis in 
Alzheimer Disease.  S100B expression was not detected in HL-60 cells with or without 
treatment with HN2.  Review of the tissue distribution of S100B shows it is highly expressed 
in neurons while expression in bone marrow cells is very low (Figure V-1).  S100B was not 
inducible by HN2 treatment in HL-60 cells. 
Expression of S100A8, which has been reported to be highly expressed in 
leukocytes, involved in chemotaxis and inflammation (Passey, Xu et al. 1999; Zhi, Zhang et 
al. 2003) was also tested.  No upregulation of S100A8 was observed with HN2 treatment 
after a time course or with various HN2 doses.  Of the other S100 family members on the 
microarray templates, none showed different expression in these gene expression profiles.  
Evidence exists suggesting functions for most S100 proteins, whereas the function of S100P 
remains unclear.  The unique response of S100P to HN2 among the S100 family indicates its 
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function may be unrelated to the function of other S100 family members, except S100Z 
(Gribenko, Hopper et al. 2001).   
S100Z forms heterodimers with S100P (Gribenko, Hopper et al. 2001) and is also 
upregulated by HN2 treatment.  S100Z is a novel S100 family member, found through yeast 
two-hybrid as an S100P interacting protein.  S100Z is a dimeric, predominantly alpha-helical 
protein that also binds calcium.  S100Z mRNA has a similar pattern of expression in tissues 
to S100P, with highest levels found in placenta, spleen and leukocytes.  S100Z gene 
expression appears to be deregulated in some tumor tissues such as lung cancer (Gribenko, 
Hopper et al. 2001). Both S100P and S100Z have two calcium binding domains with 
different binding affinities.  The upregulation of S100Z by HN2 similar to S100P suggests 
S100P and S100Z may be co-regulated in response to cross-link DNA damage, and 
potentially participate as hetero-dimers in a cellular response to this damage.  How S100P 
expression changes relate to S100Z expression changes remains to be elucidated.   
In summary, the response of S100P and S100Z to DNA cross-linking agents is 
unique among the tested S100 calcium binding protein family members.  The two genes may 
be coregulated in response to HN2, and may function as a heterodimer.  Their precise 
function remains unknown.   
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VI.   
 
S100P mRNA REGULATION IN REPONSE TO OTHER CROSS-LINKING 
AGENTS IN HL-60 CELLS 
Introduction 
S100P is upregulated by the bifunctional alkylating agent nitrogen mustard but not 
by monofunctional alkylating agents.  To determine whether this response is general to 
cross-linking agents, S100P expression in HL-60 cells treated with other cross-linking agents 
(cisplatin, MMC, and melphalan) was analyzed.  DNA cross-linking agents can cause 
monofunctional alkylation, interstrand cross-links, intrastrand cross-links, and DNA protein 
cross-links; although the interstrand cross-links appear to cause the major cytotoxic effect.  
Based on the proportion of different cross-links, DNA cross-linking agents can be divided 
into predominant interstrand cross-linkers and predominant intrastrand cross-linkers such as 
cisplatin.  The DNA cross-linking agents include mustard family agents such as nitrogen 
mustard and melphalan, and non mustard family agents including MMC and cisplatin.  The 
structures of melphalan (Figure VI-1), MMC (Figure VI-2), and cisplatin (Figure VI-3) are 
shown. 
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Figure VI-1.  Structures of melphalan and mustard family. 
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Figure VI-2.  Structure of mitomycin C. 
 
Figure VI-3.  Structure of cisplatin.  
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Materials and Methods 
Cross-linking agents.  Analytical melphalan and MMC were obtained from MP 
Biomedicals (Irvine, CA USA).  Cisplatin was obtained from Sigma (St. Louis, MO USA). 
RNA extraction.  Cells in log-phase growth with and without melphalan, MMC and 
cisplatin challenges, were harvested from 5 ml cultures.  Total RNA was prepared using 
RNeasy® Mini Kits (Qiagen Inc. Valencia, CA) and used for virtual Northern blot and real 
time quantitative PCR. 
Results 
To determine whether the induction of S100P mRNA expression is unique to HN2 
or occurs with other agents that cause cross-link DNA damage, S100P induction in HL-60 
cells was tested after treatment with the cross-linking agents melphalan, MMC, and cisplatin.  
Concentrations of melphalan used to treat HL-60 cells were 0, 2, 3, 4, 5, 6, 7, and 8 µM.  
After 24 hours, S100P mRNA levels increased up to 3.3-fold in cells treated with 3 to 8 µM 
melphalan (Figure VI-4).  HL-60 cells were also treated with MMC (IC50 = 50 nM) at 
concentrations from 5 nM to 1 µM.  After 48 hours, S100P levels by real time PCR increased 
3, 11, 13, 13, 15, and 7.5-fold with 5 nM, 25 nM, 50 nM, 100 nM and 1 µM MMC 
respectively (Figure VI-5).  S100P mRNA levels increased 20-fold in HL-60 cells 72 hours 
after treatment with 1.25 µM cisplatin (Figure VI-6), a dose with a similar toxic effect to 1 
µM HN2 on HL-60 cells by MiCK assay analysis and cell cycle flow cytometry (data not 
shown).  
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Figure VI-4.  Upregulation of S100P mRNA by melphalan. A series of melphalan doses (2, 
3, 4, 5, 6, 7, 8 µM) was used to treat HL-60 cells.  Total RNA was extracted 24 hours after 
treatment and used for real time RT-PCR amplification.   
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Figure VI-5.  Upregulation of S100P mRNA by MMC.  A series of MMC doses (control, 5, 
25, 50, 100 nM, 1 µM) were used to treat HL-60 cells.  Total RNA was extracted 48 hours 
after treatment and used for real time RT-PCR amplification.  
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Figure VI-6.  Upregulation of S100P mRNA by cisplatin.  A series of time points (control, 
72 and 96 hours) were followed on HL-60 cells treated with 1.25 µM cisplatin.  Total RNA 
was extracted and used for real time RT-PCR amplification.   
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Discussion 
To determine if the upregulation of S100P by HN2 in HL-60 cells is unique to HN2 
or a general response to agents that cause cross-link damage, HL-60 cells were challenged 
with other cross-linking agents and the expression level of S100P was tested.  S100P 
induction was seen in HL-60 cells treated with all cross-linking agents (melphalan, MMC and 
cisplatinum) tested.   
Interstrand cross-links (ICLs) constitute up to 5% of the DNA damage caused by 
nitrogen mustard and its derivatives.  These ICLs cause a major distortion of DNA 3-D 
structure (Larminat, Zhen et al. 1993; Wiencke and Wiemels 1995; Lawley and Phillips 1996; 
Dronkert and Kanaar 2001).  Nitrogen mustards cause guanine monoadducts (next to the N-
7 guanine ICLs in the sequence GpNpC) and DNA–protein cross-links, and they also react 
with RNA.  Melphalan also causes N-3 adenine adducts (Lawley and Phillips 1996).  
Mitomycin C, a natural antitumor antibiotic, forms adducts at the N-7 and N-2 position of 
guanine, intrastrand cross-links, and ICLs between the N-2 position of guanines at d(CpG) 
sequences in the minor groove (Pritsos and Sartorelli 1986; Tomasz 1995).  Both nitrogen 
mustards and MMC mainly form ICLs.  In contrast, cisplatin mainly forms intrastrand cross-
links (Chu 1994).  Cisplatin reacts with guanines to form diadducts in DNA, resulting in 65% 
d(GpG) intrastrand cross-links, 25% d(ApG) intrastrand cross-links and 5–8% ICLs 
between the guanines in the sequence d(GpC).  The structure of a cisplatin ICL incorporated 
in an oligonucleotide has been determined and reveals a major distortion of DNA 3-D 
structure.  The platinum is located in the minor groove of the DNA.  The helix displays a 
47° bending towards the minor groove and a 110° unwinding, while cytosines are extruded 
from the helix (Larminat, Zhen et al. 1993; Chu 1994; Lawley and Phillips 1996).   
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All DNA cross-linking agents that were tested upregulate S100P.  Mitomycin C and 
cisplatin strongly induce S100P.  The difference of the ability to upregulate S100P may be 
secondary to the time points that are tested.  Some cross-linking agents may upregulate 
S100P at a relatively early time point while others may to that at later time points.  The 
difference of location of DNA cross-link may also play a role in the difference.   
Thus, S100P upregulation is not restricted to nitrogen mustards or dependent on the 
type of agent causing DNA cross-link damage, suggesting S100P may be involved in a 
generic response to DNA cross-links. 
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VII.  
 
CELLULAR BEHAVIOR AFTER HN2 TREATMENT AND EXPLORATION 
OF POSSIBLE FUNCTIONS OF S100P 
To evaluate the possible function of S100P, the cellular response of S100P induction 
to DNA cross-link damage may provide clues.  When mammalian cells are treated with 
DNA cross-linking agents, they develop cross-link damage of DNA, arrest the cell cycle and 
undergo DNA repair (Murray and Meyn 1986; Mu, Bessho et al. 2000; Sancar, Lindsey-Boltz 
et al. 2004).  If the damage is too severe to repair, cells undergo apoptosis.  Since the study 
of cell death is not the goal of this project, we used a dose of cross-linking agents that caused 
minimal cell death.  If cells are able to repair the damage, they may reenter the cell cycle and 
undergo proliferation (Shima, Munroe et al. 2004; Dendouga, Gao et al. 2005), or as a result 
of the insult they may undergo differentiation (Gerson, Berger et al. 1992).  Thus analyzing 
the cellular responses to DNA cross-link damage such as cell cycle distribution, drug 
resistance, cell differentiation, and proliferation could be helpful to understanding a possible 
role of the induced S100P protein. 
HN2 causes a G2 arrest at 24h and cell growth delay in HL-60 cells  
Human myeloid leukemia HL-60 cells were treated with a range of HN2 
concentrations in order to establish a maximum tolerated dose. One micromolar HN2 did 
not induce extensive cell death [<10%, determined by detection of cells with sub-G1 DNA 
content and MiCK assay (data not shown)].  At 24 hours after addition of 1 µM HN2, an 
obvious late S/G2 arrest was detected by flow cytometric analysis of DNA content (Figure 
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II-2).  At later time points (48, 72 and 96 hours), the cell cycle DNA distribution returned to 
that of untreated cells (Figure II-2).  The effect of HN2 on the number of cells produced in 
the culture appeared as a delay at one day consistent with the transient cell cycle block 
observed at 24 hours and as an extended phase of reduced rate of cell growth (Figure VII-1).  
Despite the cell cycle return to a pattern similar to a random cycling population by 96 hours 
as measured by DNA content, the rate of cell growth did not return to that observed in the 
untreated cells until two weeks after initiating HN2 treatment.  The total number of viable 
cells in HN2 (1 µM) treated cultures did not drop below the starting level at any time, 
consistent with minimally induced cell death. 
Discussion 
S100P mRNA starts to increase 24 hours after HN2 treatment, when HL-60 cells 
appear to be arrested at S/G2 phase.  Interestingly, at this time point S100P protein 
expression in HL-60 cells remains close to the control.  Cell cycle arrest at G2 24 hours after 
HN2 treatment is a unique response of HL-60 cells to HN2 treatment.  This phenomenon 
was not observed when HL60 cells were treated with similar chemotherapeutic agents that 
don’t cause DNA cross-link damage (DME/DEE). Upregulation of S100P mRNA at 
twenty-four hours and its relationship to cell cycle arrest is still unclear. This biological role 
of S100P remains to be investigated.  The apparent G2 arrest induced by HN2 begins to 
resolve by 48 hours, but theS100P protein is not significantly upregulated until 96 hours after 
HN2 treatment, at which time the cell cycle by DNA content has returned approximately to 
normal.  4 days after HN2 treatment, cells increase the growth rate compared to the first 4 
days after treatment.  Around 2 weeks after treatment, cells are proliferating at a rate similar 
to control cells without any treatment.   This recovery could be explained by the dilution of 
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the original treated cells by passaging in culture. We did not study the kinetics of the return 
of S100P to baseline levels to determine when induced S100P is back to baseline.  However, 
as described in the next section, ICC reveals that S100P protein levels remain high at 196 
hours post-HN2 treatment.  It should be noted that a cell cycle arrest is present at 24 hours 
post treatment but by 96 hours cells have completely recovered from G2 arrest. As 
mentioned above, S100P protein does not become upregulated until 96 hours, suggesting 
that S100P does not play a role in the G2 arrest that is initiated at 24 hours. However, these 
results may indicate S100P promotes cell cycle progression from G2 arrest. 
This hypothesis could be tested in several ways, one involving attempts to knock 
down protein levels and another attempts to overexpress S100P protein.  In the first case, 
siRNA against S100P could be used to knock down the induction that occurs post drug 
treatment.  If S100P rescues the cells from the G2 arrest then the siRNA treated cells will 
not recover from their arrest.  Conversely, if S100P is constitutively overexpressed, the cells 
may never go into a G2 arrest because S100P is driving the cell cycle away from arrest.   The 
overexpression experiments may require an inducible system if the high stable 
overexpression of S100P is toxic to cells.  Alternatively the gene can be transiently 
transfected into cells along with a sortable cell surface marker such as CD8, and the 
transfected population could be sorted and analyzed (van den Heuvel and Harlow 1993).  
Finally it cannot be ruled out other molecules together with S100P or independent of S100P 
may play a role in cell cycle progression.  For example, induction of p53 may be a cause of 
the transient cell cycle arrest observed at 24 hours post drug treatment.  Ultimately the 
experiments involving direct manipulation of S100P levels, such as siRNA knockdown or 
overexpression, will be most informative for determining S100P function.  Of course 
transgenic and knockout mouse models could also be useful for this purpose. 
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Figure VII-1.  Effects of 1.0 µM HN2 on HL-60 cell growth.  Total number of cells 
produced in untreated (○) and HN2 treated (■) cultures.  Average counts from three flasks 
were plotted and the CVs averaged 12%. 
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Rechallenge of HN2 treated HL-60 cells 
HL-60 cells that had been exposed to HN2 for 2 weeks or 4 weeks were reexposed to 
HN2 and cell growth compared to cells that had not been exposed previously to HN2.  Both 
cultures that were rechallenged with HN2 showed resistance to the growth suppressing 
effects of HN2 over the 14 d period (Figure VII-2).  HL-60 cells were then re-treated six 
months after the initial exposure to HN2 and showed no resistance to the growth 
suppressing effects of HN2 (data not shown). 
Discussion 
The above findings suggest HL-60 cells with initial exposure gained resistance to 
HN2 rechallenge to some degree.  However this gained resistance does not protect cells 
completely from DNA cross-link injury since cells with preexposure do not grow as well as 
the group without rechallenge.  These findings are observed in HL-60 cells treated two or 
four weeks before. Introduction of growth factors from fresh media along with the 
passaging of the cultures may contribute to the growth curve difference.  Interestingly, 
S100P protein was found to be expressed in HL-60 cells at 196 hours after HN2 treatment 
through immunocytochemistry.    
Six months after initial exposure to DNA cross-linking agents, HL-60 cells do not 
show resistance to HN2 treatment when compared to the cells never exposed to HN2 
previously.  Though the molecular pathogenesis of the resistance is unknown, the resistance 
is not permanent.  S100P expression was also tested around 6 months after HN2 treatment.  
There is no difference of S100P expression in HL-60 cells challenged 6 months previously 
and cells without any previous treatment.   How long S100P expression lasts and how it is 
regulated remains unclear. 
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From the experiments described above, it is not known if S100P is continuously 
upregulated.  There is no direct evidence that suggests or rules out that S100P is involved in 
drug resistance.  As mentioned previously, a more extensive time course of S100P induction 
would be informative.   This would be both a time and labor intensive process.  In addition, 
the constant introduction of new media over a 6-month period may not reflect the pure 
effect of DNA cross-linking agents on S100P in HL-60 cells, which is the main goal of 
further study.   
In addition, a so-called resistant HL-60 cell line was established after multiple 
treatment of HL-60 cells with escalating doses of HN2.  This resistance to HN2 was not a 
stable phenotype and this cell line is no longer available.  S100P mRNA and protein was 
tested in “resistant” and control cell lines.  There was no significant difference between these 
two groups.  A possible role in drug resistance could explain why S100P is upregulated in 
various cancers (Gros, Ben Neriah et al. 1986).  But we did not see an upregulation of 
S100P, suggesting that S100P is unlikely to play a major role in drug resistance. 
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Figure VII-2.  Effects of re-exposing HL-60 cells to 1.0 µM HN2 on cell growth.  HL-60 
cells initially exposed to HN2 for two weeks (●) and four weeks (■) prior to no re-treatment.  
HL-60 cells initially exposed to HN2 after 2 (○) and 4 weeks (□) prior to 1.0 µM HN2 re-
treatment. HL-60 cells exposed to 1.0 µM HN2 without prior HN2 exposure (◊).  The results 
are representative of three experiments. 
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Karyotype analysis 
A karyotype analysis was completed on 20 metaphases from HL-60 cells exposed to 
HN2 for 14 d.  Three karyotypes were detected (Table 2) indicating that the culture was not 
clonal after exposure to 1 µM HN2. 
The analyses of HL-60 cells 14 d after HN2 revealed three karyotypes, which is 
inconsistent with a clonal selection during the delayed recovery phase following HN2 
exposure. 
Discussion 
From previous experiments, HL-60 cells gain resistance to a DNA cross-linking 
agent challenge to some degree two weeks or four weeks after HN2 treatment.   
Drug resistance can be gained through many different mechanisms.  One of them is 
selection of a single resistant clone after multiple treatments.  This single clone with 
mutations that help cells to be resistant to drug treatment are selected because of their 
resistance.   
HL-60 cells treated with HN2 gained resistance two weeks after treatment.  
Karyotype analysis at that time fails to detect a single clone that contributes to the resistance.  
In fact, three karyotypes were detected.   This indicates that single clone selection is not the 
mechanism involved in the drug “resistance ” in HL-60 cells treated with HN2 since two 
karyoypes were present before treatment.  The mechanism of appearance of the third 
karyotypes is not clear.  Given that the HL-60 cells were challenged with a mutagenic DNA 
cross-linking agent, DNA damage may have contributed to the development of the new 
karyotype.   
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Table 2.  A karyotype analysis was completed on 20 metaphases from HL-60 cells exposed 
to HN2 for 14 d and untreated HL-60 cells. 
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S100P and cell differentiation 
Introduction  
S100P is expressed during tumor progression in breast cancer (Guerreiro Da Silva, 
Hu et al. 2000; Mackay, Jones et al. 2003) and prostate cancer (Averboukh, Liang et al. 1996; 
Gribenko, Lopez et al. 1998; Amler, Agus et al. 2000; Mousses, Bubendorf et al. 2002).  
S100P is expressed in the early stage of esophageal epithelial cell differentiation (Sato and 
Hitomi 2002; Zhi, Zhang et al. 2003).  S100P expression is also tissue specific (Jin, Wang et 
al. 2003), selectively expressed in bone marrow, esophagus, prostate, and colon. The 
potential role of S100P in differentiation and tumorigenesis may relate to the induction of 
S100P after exposure to agents that cause cross-link DNA damage.   
Since S100P is highly expressed in HL-60 cells 96 hours after HN2 treatment, it 
would be interesting to test the differentiation status of HL-60 cells at that time point.  
CD11b is a commonly used surface marker for monocytes (Hurwitz, Raimondi et al. 1992; 
Scott, Head et al. 1994).  It was tested if this population started differentiation towards 
monocytes by detecting the cell surface marker CD11b.  HL-60 cells at time 0 and 96 hours 
without treatment and cells at 96 hours after HN2 treatment were tested for expression of 
CD11b. 
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Materials and Methods 
Antibodies and agents.  Primary Anti-S100P monoclonal mouse antibody was 
purchased from the BD biosciences (Transduction Laboratories, Lexington, KY).  Anti CD-
11b PE antibody was kindly provided by Esoterix (Brentwood, TN).  
Quantitation of CD11b positive cells protein by flow cytometry.  Cellular 
CD11b was measured in HL-60 cells from 0 to 96 hours after 1 µM HN2 treatment.  Cells 
were washed twice in PBS +2% FCS and fixed in 70% EtOH in the dark at room 
temperature for 1 hour.  Cells were then washed twice in cold 1X PBS.  A saturating amount 
(as determined by titration on HL-60 cells) of S100P and CD11b antibody were added and 
allowed to incubate in the dark at room temp for 1 hour.  A matching concentration IgG1-
Isotype tube was also prepared in the same fashion.  Cells were washed twice in PBS + 2% 
FCS.  A FITC-labeled IgG1-goat anti-mouse antibody at 1 µg/µl was added to S100P, 
CD11b and isotype tubes and incubated for 1 hour.  Cellular DNA was stained with 7-AAD.  
An FC500 cytometer (Beckman-Coulter Fullerton, CA) with a 488 nm and 633 nm 
excitation source was used for data acquisition.  S100P and CD 11b data were analyzed using 
WinList 5.0, ModFit LT 5.0 (Verity Software House, Topsham, Maine) and Excel 5.0 
(Microsoft, Seattle WA).  S100P expression was determined by comparison of each time 
point to the background protein expression as determined by the isotype control in drug 
treated and control samples.  This method was also used to measure the frequency and 
intensity of S100P expression in each cell cycle state.  Cell cycle data was determined by 
modeling in ModFit LT and analyzed using Lysys software (Becton Dickinson). 
Results 
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CD11b is a cell surface marker for monocytes.  Cell surface staining of CD11b was 
performed in nontreated HL-60 cells at zero and 96 hours, and HL-60 cells at 96 hours after 
challenge with HN2.  These HL-60 cells were also stained with S100P and 7AAD.  CD11b 
was not detected in the majority of cells in these three groups, suggesting an absence of 
monocyte differentiation in non-treated and treated HL-60 cells.  Thus there is no evidence 
that upregulation of S100P stimulates monocytic differentiate of HL-60 cells.  A more 
definitive evaluation of a role for S100P in differentiation of HL-60 cells would require 
specific ablation of S100P mRNA with siRNA as described in section I discussion.    
 
 
 84
 
 
 
 
 
 
Figure VII-3.  CD11b expression did not change significantly in HL-60 cells without or with 
HN2 treatment.  HL-60 cells with or without treatment were followed for four days.  They 
were stained with CD 11B, S100P, IgG1 isotype.  Row A: HL-60 cells without treatment at 
time 0. Row B: HL-60 cells without treatment at time 96 hours. Row C: HL-60 cells with 
HN2 treatment at time 96 hours.   
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Discussion  
Our data showed an absence of CD11b staining in majority of HL-60 cells indicative 
of monocytic differentiation in HL-60 cells 96 hours after HN2 treatment.  At 96 hours after 
HN2 treatment, S100P protein overexpression becomes evident by Western blot analysis, 
although no cell differentiation is detected.  S100P expression was detected in specific layers 
of esophageal epithelial cells (Sato and Hitomi 2002)  and may be involved in differentiation 
of these cells. The data suggest that S100P induction by HN2 does not cause monocytic 
differentiation of HL-60 cells. 
To test further a possible relationship between cell differentiation and S100P 
overexpression, one could determine S100P expression after induction of macrophage 
differentiation of HL-60 cells with phorbol ester. Elimination of S100P message through 
siRNA could also be employed to determine if S100P is required for differentiation of HL-
60 cells.  However, because of its short length and homology to other S100P gene, attempts 
to define an effective siRNA have not been successful to date.  The role of overexpressed 
S100P in HL60 differentiation could be studied in the same system previously described for 
studying cell cycle effects.  In fact, arrest of the cell cycle is often associated with cellular 
differentiation, so we hypothesize that S100P does not stimulate differentiation.  This is also 
consistent with the upregulation of S100P found in cancers, where undifferentiated, 
uncontrolled growth was observed. 
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S100P and cell cycle distribution 
Introduction  
DNA cross-linking agents such as HN2 affect, cell cycle arrest (Murray and Meyn 
1986; O'Connor, Wassermann et al. 1991; O'Connor, Ferris et al. 1992), DNA repair 
(Murray and Meyn 1986; De Silva, McHugh et al. 2000), apoptosis (O'Connor, Wassermann 
et al. 1991; Marathi, Howell et al. 1996), differentiation and proliferation (Hansson, Edgren 
et al. 1988; Scharer 2005). There is a G2 cell cycle arrest at 24 hours after HN2 challenge.  At 
later time points (48, 72 and 96 hours), the cell cycle distribution resembles a random, non-
synchronized population.  
S100P mRNA upregulation starts at 24 hours and maximizes around 96 hours.  
S100P proteins are upregulated at 96 hours.  These findings suggest S100P is not involved in 
the G2 cell cycle arrest appearing at 24 hours.  In fact on the contrary it may promote cell 
cycle progression from G2 to M.  There is no significant sub G1 population appearance in 
96 hours course from cell cycle analysis by flow cytometry, which indicates no significant cell 
death at four days after treatment.  This suggests S100P is unlikely to be directly involved in 
cell death.  It may help cell survival by promoting cell cycle progression.  To study S100P 
distribution in the cell cycle, S100P expression during the cell cycle in PHA driven normal 
lymphocytes was examined.  The expression of S100P in HL-60 cells was also checked 
without any drug challenge.   
To analyze the cell cycle distribution, 7-AAD was used to measure DNA content, 
and anti-MPM2 monoclonal antibody to label the mitotic population.  Like Propidium 
Iodide (PI), 7-AAD was used to quantitate the DNA content after having cells 
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permeabilized.  HL-60 cells and PBMCS were triply stained with S100P, 7-AAD and the 
mitosis-specific mAb, MPM2, to identify if the mitotic population overexpressed S100P.  
Material and Methods  
Cells and agents.  PHA driven peripheral blood mononuclear cells (PBMCS) were 
collected from four donors.  S100P was studied throughout the normal cell cycle by driving 
PBMCS with 10 µg PHA/ml media and assaying at 0, 24, 48, 72 and 96 hours in culture.  
This process was repeated twice with the same 4 donors assaying for S100P and DNA 
content at each time point.  
Cell cycle analysis.  2 × 106 cells stimulated with PHA were collected and fixed in 5 
ml ice-cold 70% ethanol, and stored at -20°C overnight in the dark.  The ethanol was 
removed by washing with PBS, and the cells were incubated in 500 µl 7-AAD for 30 minutes 
at room temperature in the dark.  Flow cytometric analysis of DNA content using 7-
aminoactinomycin D (7-AAD) was completed using a FACScan analyzer (Becton Dickinson, 
Mountain View, CA).  Cell cycle analysis was conducted using ModFit cell cycle software 
and WinList histogram software (Verity Software House, Topsham, ME).  Apoptotic cell 
death was quantified as the proportion of cells in the population with a subdiploid (<2N) 
DNA content.  Mitotic population was labeled by the mitotic marker MPM2. 
MPM2 and S100P immunostaining for flow cytometry has been described earlier 
(Chapter VI) 
Results 
To find the normal distribution pattern of S100P in different stages of the cell cycle, 
peripheral blood mononuclear cells (PBMCS) were analyzed.  Treatment of PBMCS with 
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PHA was used to induce cell cycling.   It was found that S100P expression increased through 
G1 and S; maximizes at G2, dropped by a half log in mitosis, and then halves as cells 
complete division, repeating the same cycle (Figure VII-4).  
S100P expression was also tested during the cell cycle in HL-60 cells without any 
drug challenge (Figure VII-5).  Similar to the findings in the PBMCS, the mitotic population, 
which was labeled by MPM2, expressed low levels of S100P.  The G2 population has the 
maximal amount of S100P expression while early G1 appears to have the lowest expression.  
In addition S100P and MPM2 were analyzed in HL-60 cells treated with HN2.  Cells with 4N 
DNA content over expressing S100P did not stain for MPM2.  Thus the subpopulation with 
S100P overexpression was not in mitosis but rather consisted of cells in G2.  Cells with 4N 
DNA content staining with MPM2 had low levels of S100P. 
Cell cycle distribution in the HN2 treated HL-60 cells is similar to untreated HL-60 
cells, except as observed previously, a G2 cell cycle arrest occurs 24 hours after HN2 
challenge (Figure VII-7).  Cell cycle distribution returns to control levels at 96 hours after 
treatment, coinciding with S100P protein induction.   
 
 89
 
0 200 400 600 800 1000
7AAD Lin
10
0
10
1
10
2
10
3
10
4
M
PM
2-
A
F4
88
Mitotocs
G2 cells
0 200 400 600 800 1000
7AAD Lin
10
0
10
1
10
2
10
3
10
4
S1
00
P-
PE
 
 
Figure VII-4.  Normal S100P distribution pattern at different cell cycle stage of PBMCS 
driven by PHA 
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Figure VII-5.  S100P distribution in HL-60 cells without drug challenge.  Mitotic population 
(red in bottom panels) does not overexpress S100P. 
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Figure VII-6.  The cell cycle distribution in HL-60 cells up to 96 hours without HN2 
challenge.  
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HL-60 cell cycle distribution after HN2 treatment
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Figure VII-7.  The cell cycle distribution in HL-60 cells up to 96 hours after HN2 challenge   
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Discussion 
S100P distribution in normal PBMCS is high in G2 and low in mitosis.  “Caretaker” 
proteins double their protein content from G1 to G2, and decrease by 50% as they progress 
through mitosis to G1.  In PBMCS, S100P expression in the G2 cell population is 
approximately ten fold greater than the lowest G1 level, and is much more than the two-fold 
ratio of caretaker proteins.  The abrupt decrease of S100P in mitosis suggests a role for 
S100P in cell cycle regulation, possibly as a checkpoint gene or a trigger for apoptosis; while 
down regulation of S100P may permit cell cycle progression through mitosis. 
This hypothesis is supported by the finding of S100P upregulation in HL-60 cells 
treated with HN2.  As shown in Figure VII-7, at 24 hours after HN2 treatment, cells are not 
cycling and there is a significant G2 arrest.  This period of time is when S100P is upregulated 
only by RNA analysis, followed by protein upregulation by Western blot and 
immunohistochemical analysis at 96 hours.  It is possible that degradation of S100P is 
required for cell cycle entry into mitosis in this setting.   Other interpretations are possible, 
and as it is clearly important to do both protein overexpression and protein knockdown to 
define the role of S100P in mitosis and cell cycle progression.  As is stated in the Conclusion 
section, S100P is only found in vertebrates, so cell cycle progression in a basic sense does 
not require S100P.  The caveat is that some fine aspect of cell cycle control in vertebrates 
could have evolved to require S100P function.   
S100P protein is upregulated around 96 hours when cells appear to have recover ed 
from the G2 cycle arrest that initiated at 24 hours.  By ICC at 196 hours it is apparent that 
S100P remains elevated, and this suggests that the elevation persists for an extended time 
beyond 96 hours. There is no significant sub-G1 population to suggest cell death is 
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occurring in the S100P elevated population. Therefore, S100P is not likely to contribute to 
cell death.  Its overexpression in the G2 population in HL-60 cells suggest it may play a role 
in cell survival, and because we don’t know if these cells are cycling it may actually be 
promoting a cell cycle arrest to allow for recovery from DNA damage.  However, it may also 
be promoting cell cycle recovery from arrest.  Again, the only way to clearly define the role 
of S100P is to overexpress the protein, similar to what occurs after drug treatment, and note 
whether the cells undergo cell cycle arrest or stimulation of proliferation. 
S100P and cell proliferation 
Introduction 
A recent publication indicates S100P can stimulate proliferation of NIH3T3 cells.  
These cells do not normally express S100P protein.  NIH3T3 cells stably expressing S100P 
were produced using standard transfection techniques (Arumugam, Simeone et al. 2003).  
S100P expression increased the proliferation rate of NIH3T3 cells to 251 ± 42% that of 
control (n = 3, p < 0.05) within 72 h. Extracellular S100P also stimulated NIH3T3 cell 
growth and survival.  In these experiments histidine-tagged S100P was expressed and 
purified from E. Coli.  Non-induced bacterial proteins were used as a control.  The addition 
of purified S100P (0.01–1000 nM) to NIH3T3 cells stimulated cell proliferation in a 
concentration-dependent manner. Effects were noted with 0.01 nM, and maximal effects 
(188 ± 23% of control, p < 0.05, n = 3) were observed with 100 nM S100P.  The effects of 
S100P on cell proliferation were also time-dependent, with a significant increase in cell 
proliferation noted within 48 hours after the addition of 100 nM S100P to the culture 
medium (Arumugam, Simeone et al. 2004). 
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The possible proliferation stimulation effect of S100P requires further study.  S100P 
is not naturally expressed in NIH3T3 cells.  In addition, this study reported that S100P 
protein is secreted into the media in S100P transfected cells.  In this thesis research project, 
S100P protein in the media of HL-60 cells was not detected, which produce endogenous 
S100P.   
Although we used the same ELISA assay to detect S100P secretion as described 
(Arumugam, Simeone et al. 2004), lack of sensitivity for ELISA or the occurrence of false 
negatives cannot be completely ruled out.  It was decided additionally to test if the media 
from the HL-60 cell culture after HN2 treatment has any effect on cell growth.  If they do, it 
will be tested if addition of purified S100P proteins has similar effect on cell growth.  
The media from HL-60 cells at different time points after treatment with HN2 was 
added to untreated HL-60 cells to determine if a secreted growth stimulatory factor was 
present.  Cell proliferation curves were compared to the cells treated with either serum free 
(negative control) or serum containing RPMI (positive control). 
Materials and Methods 
Media extraction from cells.  HL-60 cells were treated with 1 µM HN2.  Culture 
was spun down at 24, 48, 72, 96 hours after HN2 treatment and media was retained.  HL-60 
cells growing at log phase were prepared for the observation of the effect of the media.  
Cell proliferation assay.  Cell growth was analyzed by cell counting.  For studies on 
the effects of possible secreted S100P on other cells, media from HL-60 cells treated with 
HN2 at different time points was added to HL-60 in RPMI.  Control cells were treated with 
either serum-free RPMI (negative control) or serum-containing RPMI (positive control).  
Media from non-treated HL-60 cells was also used as control. 
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Results 
Media from HL-60 cells treated with 1 µM HN2 and from untreated HL-60 cells was 
collected at 24, 48, 72, and 96 hours, and used to treat HL-60 cells at log phase growth.  
Serum free RPMI –1640 and serum containing RPMI-1640 were also used as negative 
controls.  Cell counts were recorded daily for 5 days.  Growth curves were drawn and 
compared.  As expected, cells treated with serum-containing RPMI proliferated at the 
highest rate.  There was no significant difference between the cell group treated with media 
from HN2 treated and nontreated HL-60 cells.  Growth curves for HL-60 cells treated with 
media from HN2 treated and non-treated cultures at 72 and 96 hours are presented in 
(Figure VII-8).  No obvious difference was observed.  Other data are not shown.  
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Figure VII-8.  Cell proliferation assay using media taken from HL-60 cells at 72 and 96 hours 
after treatment with 1 µM HN2 and media from untreated HL-60 cells  
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Discussion 
While the exact function of S100P is not clear, a recent publication reported that 
S100P was secreted into culture and stimulated proliferation of NIH3T3 cells (Arumugam, 
Simeone et al. 2003).   
As mentioned earlier, no S100P was detected in HL-60 cell culture media by ELISA 
testing.  To eliminate the possibility that the sensitivity of ELISA was not sufficient to detect 
S100P, the media from HL-60 cells at different time points after treatment with HN2 was 
added to untreated HL-60 cells.  The added media did not stimulate proliferation of HL-60 
cells.  Although exogenous S100P reportedly stimulates NIH3T3 cell proliferation, the 
physiological relevance of this observation is questioned since S100P is not expressed in 
NIH3T3 cells, and is not secreted from HL-60 cells.  In addition, it is unclear whether HL-
60 cells have surface receptors for S100P proteins.  Lack of receptors, lack of secretion or 
both may explain the results of the experiments on S100P’s role in cell proliferation.  In HL-
60 cells, RAGE is expressed; Thus lack of RAGE is not the explanation of the test results 
(van den Heuvel and Harlow 1993).   
Another way to test S100P’s effect in cell proliferation would be to use a purified 
recombinant S100P protein.  Adding purified S100P protein to HL-60 cells in RPMI, would 
allow a direct evaluation of the effect of extracellular S100P on cell growth.   
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VIII.   
 
CONCLUSIONS AND FUTURE DIRECTIONS 
Conclusions 
Our findings: 
To better understand the transcriptional response to cross-link DNA damage, genes 
were sought that were selectively upregulated in HL-60 cells treated with HN2, but not with 
two monofunctional alkylating agents (DME, DEE).  Monofunctional agents can cause 
damage similar to HN2, but cannot cause cross-link DNA damage.   
Our analysis indicated that the calcium-binding protein S100P mRNA was selectively 
upregulated by HN2 in a time- and dose-dependent manner.  Western blot analysis 
confirmed the S100P protein level is also elevated in response to HN2 treatment, at a later 
time than the mRNA level.  ICC revealed S100P is localized in the cytoplasm of HL-60 cells.  
Flow cytometry and ICC also confirmed S100P’s upregulation by HN2 at 96 hours, 
consistent with Western blot data.  Flow cytometry also suggests a fraction of G2 population 
cells overexpresses S100P approximately 96 hours after HN2 challenge, corresponding to a 
time when cells appear to have completely overcome the G2 arrest that occurred at 24 
hours.  S100P secretion was not detected in HL-60 cells with or without HN2 challenge. 
Upregulation of S100P mRNA by HN2 is also observed in the nonhematopoietic 
cell line, Colo 320 HSR and in another hematopoietic cell line, U937.  All other DNA cross-
linking agents tested also upregulated the mRNA level of S100P in HL-60 cells.  Therefore, 
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the up-regulation of S100P by DNA cross-linking agents is neither cell line- nor drug-
specific. 
Besides S100P, S100Z is also upregulated by HN2.  It has been reported that S100P 
and S100Z can interact with each other through yeast two-hybrid screening.  Therefore it is 
possible that they may function together in response to HN2 challenge.  S100B is not 
expressed or induced in HL-60 cells.  S100A8 is highly expressed in HL-60 cells and is not 
regulated by HN2. 
Expression of S100P appears to be higher in some hematopoietic cell lines.  It was 
observed that the baseline expression of S100P mRNA is intermediate in HL-60 cells, and is 
constitutively high in both U937 cells and K562 cells, very close to the placental control that 
has the highest expression level of S100P.  S100P expression is tissue-specific in normal 
tissue; it is expressed in leukocytes, trachea, prostate, and bone marrow cells (Guerreiro Da 
Silva, Hu et al. 2000).  Along with other S100 proteins, S100P is exclusively expressed in 
vertebrates (Kretsinger 1976)), suggesting a role for these proteins in functions found only in 
higher organisms with endoskeletons.  Thus basic cell cycle control may not be a function of 
S100P or other S100 proteins, because cell division occurs in their absence.  Interestingly, 
organisms did not create a need for the S100 protein family until vertebrates had evolved.  
Selective high expression of S100P in bone marrow, the calcium binding property of S100P, 
and evolution of S100P in vertebrates suggest S100P expression may have evolved in parallel 
with the migration of hematopoiesis to its intramedullary location.  The previous findings 
plus the upregulation of S100P by HN2 and other cross-linking agents in marrow cell lines 
suggest parallels to the Fanconi (FA) protein system, a system that is also exclusively 
expressed in vertebrates, and which is involved in the cellular response to cross-link DNA 
damage and serves an unknown but critical protective role in marrow and bone.     
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S100P and cell survival: 
Although our results do not define a functional role for S100P induction, we do have 
clues as to how the protein doesn't function, which is important knowledge.  Other DNA 
damage inducible genes such as p53 and Gadd45 (Scharer 2005) will arrest the cell cycle so 
that DNA damage can be repaired. However, the induction of S100P does not result in cell 
cycle arrest.  Thus S100P is not likely involved in the growth arrest observed when cells are 
subjected to DNA damage. 
S100P may play a role in cell survival.  The critical experiment would be to prevent 
the upregulation of S100P by siRNA in response to sublethal doses of HN2 and determine 
the extent of cell death that occurs with siRNA treatment.  If S100P is important for survival 
there will be an increase in cell death upon siRNA knockdown of message and protein under 
drug treatment.  Another experiment would involve enforced expression of S100P; if there is 
a pro-survival role we would expect to see reduced death in cells overexpressing S100P. 
Analysis of cell cycle and S100P expression suggests that S100P may be involved in cell 
survival after HN2 challenge and regulation of cell passage through S/G2 to M.  This 
provides further directions for research.   
The specific increased level of S100P in a subset of G2 cells is an indication that 
following exposure to HN2, these cells exhibit a unique response associated with the 
prolonged recovery phase.  A group of cell cycle genes (cdc25c, cyclin A, cyclin B2, cdc2, 
and survivin), which function to regulate the transition of cells from G2 phase to mitosis, 
exhibits a similar pattern of G2 specific expression.  The G2 specific expression of survivin 
was recently proposed to counteract a default induction of apoptosis in the G2 phase.  
Survivin and S100P share similarities related to expression.  Both are elevated in many 
cancers and elevated expression is associated with enhanced survival in cells under stress.  
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Survivin has been implicated in mechanisms that inhibit apoptosis as well as in chromosome 
separation and cytokinesis.  S100P does not share structural features with survivin nor does 
it share the same localization within the cell.  Normal constitutive survivin is expressed 
specifically in G2 cells.  The constitutive S100P expression was maximal in G2 cells, being at 
a minimal level in mitosis and in some cells with G1 DNA content (presumably early G1 
cells).  The level progressively increased as cells replicated DNA. Unlike survivin, mitotic 
cells expressed a low level of S100P similar to that found in G1 cells.  The elevated level of 
S100P protein (96 hours after HN2), above the constitutive level, that was detected in cells 
with G2 DNA content was not associated with growth arrest, as there was no obvious 
accumulation of cells in a phase of the cell cycle.  These cell cycle genes (cdc25c, cyclin A, 
cyclin B2, cdc2, and survivin) share a number of regulatory elements in their promoter 
regions including a repressor element termed “cell cycle genes homology region” (CHR).  A 
scan of the sequence upstream of the S100P coding sequence revealed two CHR elements.  
The possibility that the cell cycle specific expression of S100P is co-regulated with these 
other genes requires further investigation.  The over-expression of S100P detected in a 
number of cancers and in cell lines capable of enhanced survival under stress supports a role 
in cellular defense mechanisms. The results are consistent with this, and also indicate that at 
least in HL-60 cells, S100P function in both untreated cells and particularly in those 
recovering from the effects of bifunctional alkylating drugs is linked to cells in the G2 phase.   
S100P, cell proliferation and anti-apoptosis:  
The S100 protein family is the largest subgroup within the superfamily of proteins 
carrying the Ca2+-binding EF-hand motif. S100 proteins have a plethora of tissue-specific 
intra- and extracellular functions.  Many S100 proteins have extracellular function through 
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Receptor for Activated Glycation End Products (RAGE) (Donato 2001). It has been shown 
in vivo that S100P can stimulate cell proliferation and cell survival through RAGE 
(Arumugam, Simeone et al. 2004).  The proliferation and survival effects of S100P 
expression were duplicated in a time- and concentration-dependent manner by the 
extracellular addition of purified S100P to wild-type NIH3T3 cells and correlated with the 
activation of extracellular-regulated kinases (Erks) and NF-KB. It was found that S100P co-
immunoprecipitated with RAGE. Furthermore, the effects of S100P on cell signaling, 
proliferation, and survival were blocked by agents that interfere with RAGE including 
administration of an amphoterin-derived peptide known to antagonize RAGE activation, 
anti-RAGE antibodies, and by expression of a dominant negative RAGE (Arumugam, 
Simeone et al. 2004). This suggests the possibility that S100P can act in an autocrine manner 
in some cells via RAGE to stimulate cell proliferation and survival. 
We found no secretion of S100P into the media of HL-60 cells with HN2 treatment, 
so it is unlikely that in HL-60 cells S100P acts in autocrine manner.  However, intracellular 
functions of stimulating cell proliferation or promoting cell survival are still possible.  It will 
be important to determine the level and activation state of proteins such as Akt, Erk and 
NF-Kb, which are involved in cell proliferation and survival, when HL-60 cells overexpress 
S100P.  Analyzing these enzymes may provide information that S100P is using these 
pathways for intracellular signal transduction.   
S100P and cancer cell migration and invasion: 
Another function of S100P may play a role in migration or invasion of cancer cells.  
When some cell types are exposed to stressful conditions such as DNA damaging agents or 
hypoxia the cellular response can include stimulation of cellular movement to exit the 
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stressful environment and find a more favorable environment.  For example the Met 
tyrosine kinase receptor under conditions of hypoxia will stimulate osteosarcoma cells to 
migrate (Pennacchietti, Michieli et al. 2003).  Expression of the related S100 protein, 
S100A4, is a poor prognostic factor for breast and colon cancer (Taylor, Herrington et al. 
2002). This is consistent with the known role of S100A4 contributing to cell invasion 
properties (Belot, Pochet et al. 2002; Filipek, Jastrzebska et al. 2002; Mackay, Jones et al. 
2003).  In support of S100P playing a role in invasion, S100P expression was found to be 
associated with later stage pancreatic cancer (Rosty, Ueki et al. 2002; Logsdon, Simeone et al. 
2003; Sato, Maitra et al. 2003).  An in vitro method to test S100P in invasion could be to 
determine if S100P overexpressing epithelial or fibroblast cells can migrate through a 
Transwell chamber.  As well the question could be asked if treatment with HN2 stimulates 
the S100P overexpressing cells to migrate or invade.  Finally, S100P overexpressing and non-
expressing cells can be tested for their ability to form metastases in nude mice.  However, it 
is not clear how these findings affect hematopoietic cells. 
DNA damage and S100P regulation 
  Our results may have implications for the upregulation of S100P that is found in 
cancer (pancreatic, colon, gastric, breast and prostate cancer).  Although S100P is 
upregulated by bifunctional agents, but not by monofunctional alkylating agents, it is 
possible that other types of DNA damage, which we have yet to investigate, could 
upregulate S100P.  The global DNA loss/gain that is the hallmark of an aneuploid cancer 
cell may in fact be a signal that is upregulating S100P (Boige, Laurent-Puig et al. 1997; 
Marton, Thein et al. 2001).   
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By contrast it has been shown that DNA mutation is not prevalent in cancer, 
specifically in colon cancer (Wang, Rago et al. 2002).  The results of this study show that 
DNA mutations are not common in the colorectal cancer genome, occurring on average 
once every 1Mb or so (Wang, Rago et al. 2002).  This mutations frequency is similar to the 
frequency in normal cells, suggesting that somatic mutations are not occurring at an elevated 
frequency.  It is suggested that these mutations are not a DNA damage signal causing the 
upregulation of S100P. Therefore, it is possible that the elevated deletion and amplification 
of chromosomal DNA is a generates a DNA alteration signal that might upregulate S100P. 
This could potentially be tested in mouse transgenic models of cancer, where the 
current mouse models do not typically show the aneuploidy found in human cancer.  
Alternatively, given our observations we could examine whether patients who had received 
prior DNA-damaging chemotherapy, upregulate S100P.  If patients had received 
chemotherapy prior to having an analysis of their S100P status, it might complicate whether 
S100P was upregulated by the cancer cell as part of its normal physiology, or whether the 
upregulation was due to the response of the cancer cell to chemotherapy.  In the study of 
pancreatic cancer, it was the case that patients had not received prior chemotherapy, thus 
suggesting that in this cancer the upregulation is not a therapy-induced event. 
S100 mouse models:   
Transgenic or knock out mouse models of S100P may help to determine S100P’s 
function in vivo.  There are transgenic or knock out models with other S100 genes such as 
S100B.  Neither S100B inactivation nor overexpression results in abnormalities in mice 
development.   S100B knockout mice show enhanced plasticity in glial cells with enhanced 
fear memory, suggesting S100B may be involved in information processing.  Lack of S100B 
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resulted in decreased calcium handling capacity in astrocytes (Marenholz I 2004).  Increased 
S100A1 expression resulted in increased myocardial performance under baseline conditions.  
In an S100A1 knock out model, reduced contraction and relaxation rates of myocardial 
muscles were observed (Marenholz I 2004).  In mouse models, knock out of S100A9 did not 
show any abnormal phenotypes.  Lack of S100A8 led to resorption of the embryo by the 
mother, indicating a nonredundant lethal function of S100A8 (Marenholz I 2004).  S100A4 
is a tumor associated S100 protein.  Overexpression of S100A4 enhanced the metastatic 
ability of mammary tumors.  Since S100A4 stimulated neovasculization, that may partly 
explain why S100A4 has tumor promoting function.  However, it was found that S100A4 
null mice developed more spontaneous tumors than wild type controls, possibly because of 
destabilization of p53 since S100A4 is found to interact with p53 (Marenholz I 2004).  
Therefore the cellular context and environment may play a key role in determining the result 
of S100A4 function, as both overexpression and underexpression can be shown to stimulate 
aspects of cancer growth. 
There are no established knockout or transgenic mice model of S100P.  Knocking 
out or transgenic expression of S100P in mice and analyzing the phenotypes of the mice 
might be helpful to understand the function of S100P.  There are a few possibilities.  S100P 
knock out mice may be lethal.  If that is the case, it suggests S100P is a nonredundant 
protein and is important in development.  It may then be attempted to do a conditional 
knockout in adult mice.  S100P knockout mice may not show any obvious phenotype 
physiologically.   Then it may be important to determine the response of S100P knock-out 
or overexpressing mice to DNA cross-linking agents and the development of any kind of 
malignancy including hematopoietic malignancies.  If those mice do show a phenotype, it 
can provide direction to study the function of S100P.     
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S100P, MDS and MDR-AML: 
S100P is a novel gene involved in the response to cross-link DNA damage.  This 
observation may be valuable because of the apparent involvement of cross-link DNA 
damage in the pathogenesis of MDS and MDR-AML.  We found that S100P is upregulated 
by DNA cross-linking agents such as HN2 in HL-60 cells.  Thus it is possible S100P may 
play a role in the pathogenesis of these groups of diseases.  A group from Germany have 
reported different levels of S100P message between CD34 positive cells from bone marrow 
in low grade MDS and high grade MDS patients (Hofmann WK 2002).  CD34 positive cells 
were isolated in three groups of patients, including healthy controls, low grade MDS and 
high grade MDS.  Patients with refractory anemia are considered low grade MDS and 
patients with RAEB are considered high grade MDS.  S100P mRNA is expressed at lower 
level in low grade MDS, compared to healthy controls and patients with high grade MDS.   
The protein expression pattern of S100P in myeloid neoplasia, specifically MDS, 
TDN-AML, and MDR-AML may be tested through ICC or flow cytometry and the RNA 
expression of S100P in these patients can be tested by in situ hybridization.  Further 
information of S100P expression in the bone marrow of these patients may provide insight 
to a possible role of S100P in the pathogenesis of MDS and MDR-AML. 
Upregulation of S100P expression, a specific response to bifunctional alkylating 
drugs, may provide new insight into cellular defense mechanisms, cell cycle regulation in 
response to these agents, and the pathogenesis of both diseases caused by these agents 
(MDS, AML) and syndromes associated with abnormal responses to these agents (FA, ataxia 
telangiectasia). 
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Future Directions 
The definitive biological function of S100P is not known.  However, many 
publications suggest possible functions.  Researchers have found unique expression patterns 
of S100P in different cancers, such as breast cancer, prostate cancer, esophageal cancer and 
pancreatic cancers (Averboukh, Liang et al. 1996; Amler, Agus et al. 2000; Mousses, 
Bubendorf et al. 2002; Sato and Hitomi 2002; Mackay, Jones et al. 2003; Zhi, Zhang et al. 
2003).  Others have tried to clarify S100P’s function by manipulating its expression in S100P 
null NIH3T3 cells.  S100P protein was found to be secreted in this artificial system.  
Addition of purified S100P to media containing NIH3T3 cells stimulates cell proliferation 
(Arumugam, Simeone et al. 2004). Another interesting finding is that S100P is upregulated in 
doxorubicin resistant colon cancer cell lines (Bertram, Palfner et al. 1998).  S100P transfected 
NIH 3T3 cells were found to tolerate chemotherapeutic agents better than wild type NIH 
3T3 cells (Arumugam, Simeone et al. 2004).  
Understanding the biological function of S100P will require extensive work.  Here I 
propose a few strategies to understand the function of S100P:  
The first is to block S100P expression in cells or cell lines by siRNA.  S100P protein 
expression can be knocked out using RNA silencing technology, by transfecting an RNA 
expression vector with an appropriate siRNA insert.  RNA silencing is a fast and efficient 
knock out compared with the traditional animal knock out model.  However, S100P is a 
member of a family of 21 proteins.  Since the genes for these proteins share close to 50% 
homology, there are potential technical difficulties in specifically knocking out S100P 
without affecting other S100 protein genes.  After successfully knocking out S100P, the 
difference in cellular phenotype between the wild type and S100P knock out cells can be 
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compared, which will provide clues about the function of S100P.  Drug resistance to HN2 
and the gene expression patterns of these two cell lines will also be compared, to enable 
identification of proteins or protein families that are direct or indirect candidate targets of 
S100P.   
The second method is to overexpress S100P in cells or cell lines that lack S100P 
expression.  The difference in cellular phenotype between the wild type and cells with S100P 
overexpression can be compared, which will provide more clues about the function of 
S100P.  DifferenceS of resistance to HN2 and the gene expression patterns of these two cell 
lines will also be compared to enable identification of proteins or protein families that are 
direct or indirect candidate targets of S100P.   
The third method for exploring the function of S100P is to identify S100P 
interacting proteins.  Using immuoprecipitation technology and yeast two-hybrid analysis, 
proteins that interact with S100P can be isolated.  If the selected proteins’ functions are 
known, studying the function of these proteins will be helpful to figure out the biological 
function of S100P.  A potential problem with this strategy is that functions of the selected 
proteins may be unknown.  For example, S100P was found to interact with S100Z through a 
yeast two-hybrid analysis.  S100Z was found to be a new S100 family member through this, 
so it is even more novel than S100P.  The functions of both S100P and S100Z are unknown. 
The fourth strategy is to study the expression pattern of S100P in myeloid neoplasia, 
specifically MDS, TDN-AML, and MDR-AML.  Since S100P expression is uniquely 
upregulated by DNA cross-link damage, which has been associated with MDS and MDR-
AML, it will be interesting to test S100P expression in healthy controls, MDS patients, and 
MDR-AML patients.  Because of similarities in S100P and Fanconi Anemia (FA) proteins, 
expression of S100P in FA would also be interesting.  Different S100P expression patterns 
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between low and high grade MDS, or between TDN-AML and MDR-AML, may be 
analogous to the S100P expression change after HN2 challenge in the cell lines, and may 
suggest a function of S100P in the pathogenesis of MDS and MDR-AML.  The expression 
of S100P could be detected by ICC and flow cytometry with S100P antibody.   
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